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Retinitis pigmentosa (RP) is a common inherited form of blindness, affecting 
about 1 in every 4,000 people in most populations worldwide. It is a heterogeneous 
group of retinal degenerative diseases characterized by progressive visual 
impairment usually leading to blindness. There are different modes of inheritance: 
autosomal dominant (ADRP), found in 15-20% of all cases; autosomal recessive in 
20-25%; X-linked recessive 10-15%; and simplex (family history absent) 40-55%. 
For each mode, multiple genetic loci have been found and to-date totally more than 
50 RP chromosomal loci are known. Over 100 RP causative mutations have been 
found in the rhodopsin gene (RHO), mostly missense changes, accounting for 25-
30% of ADRP and representing the most common cause of RP. Mutations in 
another gene, RPl, reported in 1999, cause at least 7% of ADRP. Known RPl 
mutations all lead to premature termination codons predicted to truncate the RPl 
molecule. However, the function of RPl is unclear and RPl mutations have not 
been reported in non-Caucasians. 
This thesis attempts to: (1) discover novel mutations and estimate the 
prevalence of RHO and RPl mutations among Chinese RP patients; (2) discover 
sequence alterations in RPJ that might indicate the function of the protein; (3) assess 
the diagnostic value of RHO and RPl mutations for RP; (4) initiate a genetic 
database of RP in Hong Kong. 
We recruited 101 unrelated Chinese RP patients and 190 control subjects from 
‘ the Hong Kong Eye Hospital and the Prince of Wales Hospital Eye Clinic after 
i 
giving complete ophthalmologic investigations. Relatives of some patients were 
also recruited and examined. All control subjects were aged above 60. Genomic 
DNA was extracted from peripheral venous blood samples. All coding exons and 
splice sites of RHO and RPl were amplified by polymerase chain reaction for 
detection of sequence alterations by conformation sensitive gel electrophoresis and 
direct sequencing. 
Two probable RHO mutations were identified, each in one family: a novel 1-bp 
deletion 521 IdelC and a previously reported Pro347Leu. Offspring of the two index 
patients carrying the respective base change did not have RP but were developing 
symptoms. These two mutations have potential use for molecular diagnosis of RP. 
The calculated frequency of patients carrying RHO and RPl mutations in this 
population is less than 7% (2/101=2.0%, 95% confidence interval: 0.2-7.0%) and 
6% (1/101=1.0%，95% confidence interval: 0.0-5.4%), respectively. In RPl, one 
patient had Arg677ter, which is a common mutation among Caucasians. Although 
nine novel RPl base changes were found, none of them definitely associated with 
RP. A novel Argl933ter truncation, however, was identified in a control. It implies 
that the part of RPl between amino acids 1052 and 1933 appears necessary to 
prevent RP while presence of the C-terminal 224 amino acids of RPl may not block 
RP, The large number of probable benign variants in RPl is unexpected. 
The mutation patterns of RHO and RPl in Chinese RP patients and in 
Caucasians are different. Our results form a preliminary foundation for 
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Chapter 1 Introduction 
1.1 Retinitis Pigmentosa (RP) 
Retinitis pigmentosa is among the most common inherited forms of 
blindness, affecting about 1 in every 4,000 people in all ethnic groups worldwide 
(Ingleheam, 1998b). It is a heterogeneous group of retinal degenerative diseases 
characterized by progressive visual impairment, very often leading to blindness. 
The course is intractable, with no effective treatment at present. Over 50 different 
genetic loci have been found to be associated with RP (Sullivan et al., 1996). 
1.1.1 Molecular genetics 
Genetic subdivisions of RP have been based on the mode of segregation 
within a family: autosomal dominant (ADRP), which is found in 15-20% of all 
cases; autosomal recessive (ARRP), which comprises 20-25% of cases; X-linked 
recessive (XLRP) in 10-15%, and simplex (SRP, when family history is absent) in 
40-55% (Guillonneau et al., 1999). For each mode of segregation, multiple genes 
have been identified (Table 1-1). Molecular genetic studies to date have identified 
mutations in at least 14 genes that cause forms of non-syndromic RP. Among them, 
five are associated with ADRP, seven with ARRP and two with XLRP. 
Additionally, there are not less than 14 other RP loci for which the associations with 
various forms of RP are evident but the defective genes have not yet been identified 
, (http://www.sph.uth.tmc.edu/Retnet/). Among all the known RP causative genes， 
1 
mutations in the rhodopsin gene {RHO) account for 10% of all cases and represent 
the most common known cause of the disease (http://www.sph.uth.tmc.edu/Retnet/). 
1.1.2 Clinical features 
Typical history is the onset of progressive poor night vision and occasionally 
poor peripheral vision in the first or second decade of life. Central visual loss is 
rarely the presenting symptom except with inverse RP or cone-rod dystrophy. 
) 
Visual acuity is usually preserved until the later stages. The symptoms of classic RP 
reflect the sequential degeneration of the rod cells followed by the cone cells. 
1 
Ocular findings comprise atrophic changes of the retinal pigment epithelium i 
j (RPE) followed by gradual appearance of melanin-containing structures in the | 
f 5 
retinal vascular layer and around Muller cells causing the ‘bone-spicule，like I 
i 
pigmentation. Typical fundus appearance includes the triad of (1) attenuated I 
arterioles, (2) bone-spicule pigmentation (mostly paravenular and midperipheral), 
and (3) waxy pallor of the optic disc (Figure 1-1). Macula may be involved. 
Myopia is relatively frequent, as is subcapsular posterior cataract and destruction of 
the vitreous usually in patients older than 40. In some early cases, | 
electroretinography (ERG) can help with the diagnosis. There is a reduced 丨 
amplitude of the scotopic and photopic b-wave and a delay in time between the flash 
of light and peak of the b-wave. When monitoring the disease by Ganzfeld ERG, 




In spite of the above common phenotypic features, the term RP actually 
consists of a group of clinically heterogeneous disorders. Significant differences are 
found in the sequence of onset of symptoms, degree of morphological changes, 
progression of visual disability, and association with systemic disease. RP is also a 
component of over 30 syndromes, most of which show autosomal recessive 
inheritance (Pagon，1993). Examples include Usher syndrome (deafness), Bardet-
Biedl syndrome (Polydactyly, obesity, mental retardation, and hypogenitalism) and 
Refsum disease (polyneuritis and ataxia). 
Massof and Finkelstein (1987) suggested a two-stage hypothesis of visual 
field loss in RP, with an initial slow progression, followed, at an individual critical � 
age，by a rapid and exponential loss of field area. Critical age was on average 32 I 
years in ADRP, 20 years in X-linked RP, and between these two ages in ARRP. I 
I 
The high critical age for ADRP follows the general clinical impression that ADRP | 
I r 
are relatively mild. Nonetheless standard deviation was more than one decade in I 
each group of RP suggesting both a considerable heterogeneity within a group and ! 
an overlap among them. 
1.1.3 Clinical classifications of RP 
The most widely accepted clinical classification systems of ADRP are based 
on differences in loss of rod and cone function. Type 1 of Massof and Finkelstein 
(1981) designates an early and diffuse loss of rod function followed by a progressive 
loss of cone function. In type 2，there is a regionally progressing and concomitant 
“ loss of both rod and cone photoreceptor function. In comparison to type 1, type 2 
3 
patients usually have a later onset of night blindness, and visual fields are better 
preserved. Their differential clinical presentations indicate a more favorable visual 
prognosis in type 2. 
Types 1 and 2 of Massof and Findelstein (1981) correspond well to the ‘D，-
type and the ‘R，-type of Lyness et al. (1985). On ERG testing, D-type patients have 
! no measurable rod function, whereas R-type patients have usually normal or reduced j 
- i rod signals with increased peak times. Cone signals are reduced in most D-type | 
|| 
cases，and are either normal or reduced in most R-type patients. Cone peak times |丨 
i� 
may be normal or delayed in both types. Blanton et al. (1991) commented, however, | 
that there was ‘no remarkable clinical disparity in the expression of disease caused 
by the different loci' identified by linkage studies. 
1.2 Molecular Biology of Rhodopsin 
1.2.1 Anatomy and functions of human retina 
The retina is the innermost of the three coats of the eye. This layer is in the 
image plane of the eye's optical system and is responsible for converting relevant 
information from the image of the external environment into neural impulses that are 
transmitted to the brain for decoding and analysis. It consists of two primary layers: 
an inner neurosensory retina and an outer simple epithelium, the retinal pigment 
epithelium (RPE). The retina consists of several cell types of which neural cells 
predominate. The three principal neuron cell types that relay impulses generated by 
1 
‘ light are photoreceptors, bipolar cells, and ganglion cells. There are two types of 
4 ； I 
photoreceptors in the human eye: rods and cones. There are approximately 115 
million rods and 6.5 million cones in the human eye. Rods are responsible for 
sensing contrast, brightness, and motion, while cones serve fine resolution, spatial 
resolution, and color vision. The density of rods and cones varies in different 
regions of the retina, the periphery being rod-dominated whilst cone density 
increases nearer the macula, the fovea being exclusively cones. Each photoreceptor 
consists of a long narrow cell with an inner and outer segment joined by a 
1 
connecting stalk consisting of a modified cilium. It contains the visual pigments that ! 
are responsible for absorption of light and initiation of the neuroelectrical impulse. 
I 
Rods are long (100-120 |im) slender cells whose outer segment contains the visual 
pigment rhodopsin within the disks (up to 100 per cell) that are enclosed by a single 
1 
cell membrane (Figure 1-3). The disks are produced at the base of the outer segment I 
and over the course of 10 days travel to the tips, which are enclosed by the apical 
microvilli of the RPE. Here they are phagocytosed by the RPE cells in a circadian 
manner，predominantly shed in the early morning. The cilium acts as a conduit for 
metabolites and lipids between the inner and outer segments. Metabolic 
disturbances in the photoreceptors may lead to disturbances in visual pigment or 
photoreceptor membrane (lipid) synthesis. 
1.2.2 Physiology of rhodopsin 
The rhodopsin molecule has 7 transmembrane domains with the carboxyl-
terminal in the cytoplasm and the amino-terminal in the intradiscal space or 
‘ extracellular surface (Figure 1-2). It consists of opsin, an apoprotein, and 11-m-
5 i 
丨 [ 
retinal, a chromophore. Opsin is synthesized by the rough endoplasmic reticulum in 
the photoreceptor inner segment and transported through the cistemae of the Golgi 
complex. Post-translational modifications include acetylation of opsin at its amino-
terminus and glycosylation of two asparagine residues near the amino-terminal 
(Figure 1-2). Subsequently, opsin is transported by post-Golgi vesicles to the rod 
outer segment, and inserted into the plasma membrane at the level of the connecting 
cilium. A recent report provides evidence that rhodopsin is transported in the 
membrane of the connecting cilium from the inner segment to the outer segment 
(Wolfrum et al.，2000). 
Disks are formed by the evagination of the plasma membrane at the junction 
between the inner and outer segments (Figure 1-3). Once properly localized in the 
rod outer segment, opsin acquires vitamin A (11-cis-retinal) at the base of the rod 
outer segment, and this confers light sensitivity on the protein now called rhodopsin 
(Berson, 1990). It constitutes up to 85% of the total amount of protein present in 
the rod outer segment (van Soest et a l , 1999). Almost all of the over 100 mutant 
rhodopsin alleles identified are associated with ADRP (van Soest et al., 1999; 
Martinez-Gimeno et al., 2000), indicating that many amino acids in the rhodopsin 
molecule are critical for the normal functioning of rhodopsin. A normal rod 
photoreceptor sheds about 10% of its outer segment discs at its apex after light onset 
and renews a corresponding amount of outer segment discs at its base over the 
course of each day (Bok, 1985). This daily renewal and shedding of outer segment 
discs is a delicate process that places a metabolic burden on the photoreceptor and 
RPE cells. Patients with mutations in rhodopsin may shed abnormally large 
6 
fractions of rod outer segments after light onset, and their rods are slow to renew 
their pre-light onset outer segment length. This eventually leads to inappropriately 
rapid and excessive rod photoreceptor cell death (Berson, 1996). 
1.2.3 Rhodopsin cycle and the visual transduction cascade 
Rhodopsin is the photosensitive molecule in the discs of rod cells. 
Photoisomerization of retinal from 11 -cis to aW-trans induces a conformational 
change in opsin, leading to activation of the photoreceptor G-protein transducin, 
thereby initiating the phototransduction cascade. Transducin stimulates cyclic 
guanosine monophosphate (cGMP) phosphodiesterase to hydrolyze cGMP. The 
resulting decrease in cGMP concentration closes the cGMP-gated cation channels 
(CNCG) in the photoreceptor plasma membrane (Figure 1-4), thus disrupting the 
influx of sodium and calcium. The decline in sodium concentration leads to 
hyperpolarization of the entire cell membrane, slowing down of ongoing transmitter 
release at the synaptic terminal, and signaling of the light stimulus to adjacent 
neurons (Stryer, 1991). 
On the other hand, the decline in calcium concentration mediates the 
recovery of the photoreceptor cell after a bleach of light (Figure 1-4). This is as 
important for maintaining sensitivity in vision as the cell's ability to respond to a 
single photon. Deactivation of rhodopsin starts with phosphorylation by rhodopsin 
kinase at serine and threonine residues in the carboxyl terminal region of the protein 
(Dorey et al.，1999). One function of phosphorylated rhodopsin is to activate 
i airestin which can then bind to other regions of the surface of the photoactivated 
7 
rhodopsin, thereby blocking the binding of transducin and preventing further 
activation of the phosphodiesterase (Hargrave et al.，1992; Puig et al.，1995). 
The complex of arrestin with phosphorylated rhodopsin decays slowly and 
can be monitored by the inhibition of the ability of protein phosphatase 2A to 
dephosphorylate phosphorylated rhodopsin (Palczewski et al.，1989). Dissociation 
of all-rra«5-retinal from the complex is the key step that facilitates the release of 
arrestin (Hofmann et al.，1992). Dissociation of all-rran^-retinal from rhodopsin's 
retinal binding site makes possible the regeneration of rhodopsin by rebinding of 11-
cw-retinal and the restoration of light sensitivity to rhodopsin. 
Therefore, the rhodopsin molecule has distinct regions that are specialized 
for light capture, initiation of the phototransduction cascade, and rapid deactivation 
after light absorption. 
1.2.4 The human rhodopsin gene (RHO) 
The human rhodopsin gene has been localized on the long arm of 
chromosome 3’ in the region of 3q21-25 (Nathans and Hogness, 1984; Nathans et 
al.，1986b). The gene spans about 5.5 kilobases with a coding sequence of 1044 
base pairs distributed over 5 exons encoding 348 amino acids residues (Figure 1-5). 
1.2.5 RHO Mutations 
Mutations in the gene encoding rhodopsin lead to retinal degeneration in 
species from Drosophila (Colley et al., 1995) to man. To date, more than 100 
mutations have been identified within RHO, the great majority in the autosomal 
8 
dominant form of the disease (http://www.sph.uth.tmc.edu/Retnet/). A few RHO 
mutations cause recessive forms of RP or congenital night blindness (Humphries et 
al” 1992; Rosenfeld et al.，1992a; Sieving et al” 1992; Dryja et al.，1993; Al-Jandal 
et al., 1999). Of the many mutations reported in RHO, around 90% are single base 
substitutions (Gal et al., 1997). The remaining mutations consist of deletions and/or 
insertions. Five small deletions (ranging from 1-12 base pairs), one gross deletion 
and one gross insertion and duplication have been reported according to the Human 
Gene Mutation Database (http://www.uwcm.ac.uk/uwcm/mg/). Most of these 
sequence variations occur in exon 5 of the gene (Gal et al” 1997). 
Mutations can be found in each domain of the rhodopsin molecule: the 
cytoplasmic surface, the transmembrane region, and the intradiscal surface. They 
may lead to retinal degeneration through several different pathways (Gal et al.’ 
1997). One critical amino acid in rhodopsin is Lys296, the site of attachment to 
retinal. The Lys296Glu mutation has been found in ADRP families (Keen et al., 
1991). 
Point mutations Asnl5Ser (Fujiki et a l , 1995)，Thrl7Met (Fujiki et al” 1992)， 
Thr58Arg (Nakazawa et al.，1991)，Glul81Lys (Saga et al , 1994) and Pro347Leu 
(Nakazawa et al” 1991; Fujiki et al., 1992) in RHO were reported in Japanese ADRP 
patients. Pro23His could not be found in any of them. Kawano et al. (1995) 
reported three polymorphisms, A269G, G5145A, and C5321A in the non-coding 
regions in 36 unrelated patients with ADRP, 23 patients with ARRP, and 67 normal 
4 controls. Their frequencies were 52%, 36%, and 5%, respectively. There was no 
9 
significant difference in the frequencies of these polymorphisms among these three 
groups of study subjects. 
1.2.6 Frequencies & phenotypes of RHO mutations 
RHO mutations account for about 25% of all ADRP cases in continental 
Europe (Bunge et al , 1993), in the UK (Ingleheam et al., 1992a), and in North 
America (Sung et al., 1991b; Macke et al” 1993; Dryja et al., 2000). The frequency 
of rhodopsin mutations among ADRP patients in Japan seems to be less (Shiono et 
al., 1992; Saga et al., 1994). 
In general, ADRP patients caused by RHO mutations fall either into the type 
1/D category described by Massof and Finkelstein (1981) and Lyness et al. (1985)， 
or have sector RP as described by Moore et al. (1992). This latter category consists 
mainly of mutations in the first exon of the gene and therefore at the amino-terminus 
of the protein or in the first transmembrane domain. As yet, sector RP has not been 
assigned to any other locus, and therefore appears to be uniquely associated with 
mutations in rhodopsin. Sandberg et al. (1995) investigated whether or not the 
severity of ADRP was dependent on the location of the corresponding RHO 
mutations and found significant differences. Visual function was better in patients 
with mutations in the intradiscal domain, i.e. toward the N-terminal, and worse in 
patients with mutations altering the cytoplasmic domain, i.e. toward the C-terminal. 
Pro23His is the first mutation found in RHO and also the most common mutation in 
North American patients, accounting for 12% of ADRP (Dryja et a l , 1990a’ 1991). 
But this mutation has not been found elsewhere (Sharma et al , 1999; Dryja et a l , 
1 0 
2000). The second most common mutation is Pro347Leu, accounting for about 3.6-
5% of ADRP patients (Sharma et al , 1999; Dryja et al., 2000). Six different 
missense mutations at this position have been identified as Pro347Thr, Pro347Ala, 
Pro347Ser, Pro347Gln, Pro347Arg, and Pro347Leu (http://www.irpa.org/sci-
news/rhomut.htm). Thus Pro347 is a mutation hotspot in RHO. By directly 
comparing visual functions of patients with the Pro23His and the Pro347Leu alleles, 
it was found that Pro23His caused milder disease than Pro347Leu (Berson et al.， 
1991b). Type 1 is relatively frequent in ADRP patients with rhodopsin mutations 
(Gal et al , 1997). 
To define the basis for ADRP caused by RHO, two types of experimental 
approaches have been used: expression of mutant forms of rhodopsin in tissue 
culture cells (in vitro study); and production of transgenic animals expressing mutant 
forms of rhodopsin (in vivo study). 
1.2.7 Findings of in vitro experiments 
Based on studies in cultured embryonic kidney cell lines, dominant RHO 
mutations have been divided into class I (15%) and class II (85%) (Sung et al , 
1991a; 1993). Class I mutants resemble wild type in yield, electrophoretic pattern, 
regenerability with 11-m-retinal, and subcellular localization. Class II mutants are 
produced at lower levels than the wild type, accumulate predominantly in the 
endoplasmic reticulum, and bind W-cis retinal to a variable extent. This class 
appears to be defective in thermal stability/folding. Mutations of class I have been 
predominantly found clustering in the first transmembrane domain and at the 
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extreme carboxyl terminus, whereas mutations of class II were found mainly in the 
transmembrane and extracellular domains (Sung et al” 1993). A third class of 
mutants, such as Lys296Glu, constitutively activate transducin in vitro (Robinson et 
al, 1992), and may cause degeneration of the photoreceptor cells as a result of 
persistent stimulation of the phototransduction pathway. However, expression study 
of rhodopsin in mice revealed that the mutant protein was permanently 
phosphorylated and inactivated by arrestin (Li et al.，1995). Therefore, it is highly 
likely that the continuous shutoff of the cascade triggers the photoreceptor 
degeneration. 
Other in vitro studies implicated the C-terminal domain of rhodopsin in its 
trafficking on specialized post-Golgi membranes to the rod outer segment (Deretic et 
al, 1998; Green et al , 2000). 
1.2.8 Findings in animal models 
Because of the lack of natural animal models of human rhodopsin mutations, 
transgenic mice carrying mutant constructs have been used. Many transgenic strains 
have been prepared in which abnormal rhodopsin genes have been inserted, 
producing offspring resembling the different forms of human RP. These include 
mice (Olsson et al., 1992)，rats (Lewin et al , 1998; Green et al., 2000), and pigs 
(Fetters et a l , 1997). The rod cells invariably degenerate and die as a result of the 
mutation. Apoptosis has been shown to play a major role in this process (Chang et 
‘ al., 1993; Portera-Cailliau, et al., 1994; Wong et al , 1997). The ERG changes in 
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mice were paralleled by decreased rhodopsin levels, a situation similar to the human 
disease (Kemp et al.，1992). 
The C-terminal sequence QVS(A)PA is highly conserved among vertebrate 
opsins, such as the rabbit, mouse, pig, sheep, cow and rat. Of 65 reported vertebrate 
opsin sequences, 32 have the above sequence at the C terminus (www.gpcr.org/7tm). 
A lack of recognition of this sequence because of mutations in the last five amino 
acids, results in abnormal post-Golgi membrane formation and in an aberrant 
subcellular localization of rhodopsin in transgenic mice (Sung et a l , 1994; Li et al , 
1996). 
Animal studies suggested that all dominant mutations in RHO, except for the 
codon 296 aberration, generate a protein that is defective in folding or transport and, 
therefore, will not be incorporated into the membrane (Naash et al., 1993; Roof et 
al., 1994; Sung et al., 1994; Colley et al.，1995; Goto et al., 1995; Li et al., 1996). 
This leads to a 50% reduction of the amount of functional rhodopsin in the cell 
membrane, and the accumulation of large amounts of mutant protein in the 
photoreceptor cells. The 50% reduction in rhodopsin does not create the RP 
phenotype, as is demonstrated in humans and mice heterozygous for a null mutation 
in RHO (Lem et al., 1999; Humphries et al., 1997; Rosenfeld et al.，1992a，b). In 
contrast, the over-expression of normal opsin levels leads to photoreceptor cell 
degeneration in mice (Olsson et al., 1992). Therefore, it is possible that the 
accumulation of rhodopsin, and the consequent disruption of internal processes, such 
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as the renewal and shedding of the rod outer segment, may trigger cell death. 
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Nevertheless, a study of photoreceptor degeneration in chimeric mice 
derived from the fusion of Pro347Ser transgenic and wild type embryos indicated 
that the mechanism of rhodopsin-induced cell death may be more complex (Huang 
et al., 1993). In such chimeric mouse retinas, which contained both normal and 
transgenic photoreceptors distributed in patches, photoreceptor degeneration was 
spatially uniform, affecting both normal and transgenic photoreceptors. This implies 
that the biochemical pathways leading to photoreceptor cell death are not completely 
cell autonomous and suggests a role for cell-cell interactions, perhaps via trophic 
factors. Besides, this finding may shed light on the mechanisms of cone 
photoreceptor death caused by mutations in rod-specific genes. Although rods die 
by apoptosis, which normally avoids release of potentially toxic cellular metabolites 
that would create problems of poisoning or inflammation and therefore prevents 
extension of cellular breakdown to surrounding regions of tissue, it seems 
nevertheless possible that degeneration of the abundant rods (about 20 times more 
numerous than cones in many mammalian species, including man) could exert 
adverse effects on the adjacent cones. A second explanation is that rods produce 
some kind of signal that is essential for maintaining cone viability, so that the 
disappearance of rods for whatever reason would deprive the cones of this signal and 
trigger their degeneration. Both circumstantial evidence and recent experimental 
findings suggest that such rod-cone interactions do exist and one can intervene to 
limit or prevent secondary cone death (Hicks et al.，1999). 
< 
1.2.9 Findings in human 
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To understand the disease process in man, Cideciyan et al. (1998) studied 
heterozygotes with 18 different rhodopsin gene mutations by using noninvasive tests 
of rod and cone function and retinal histopathology. Disease manifested as a loss of 
rod photoreceptor outer segments, not singly but in microscopic patches that 
coalesce into larger irregular areas of degeneration. Cone outer segment function 
remained normal until >75% of rod outer segments were lost. The topography of 
cone loss coincided with that of rod loss. This temporal and spatial dependence of 
cone survival on rods lent support to the hypothesis of trophic interactions between 
photoreceptors. 
1.3 Molecular Biology of RPl 
In 1999，RPl was identified as the fifth gene known to harbor ADRP-
causing mutations, after RHO, RDS, CRX and NRL, which encode rhodopsin, retinal 
degeneration slow, cone-rod otx-like photoreceptor homeobox transcription factor 
and neural retina leucine zipper, respectively 
(www.sph.uth.tmc.edu/RetNet/disease.htm). It is on chromosome 8q l l -q l3 (Pierce 
et al., 1999; Sullivan et al” 1999). The RPl gene has four exons, with the initiation 
codon being present in exon 2 (Figure 1-6). Its mRNA is �7 _ bp long and is 
predicted to encode a protein 2156 amino acids in length with a calculated molecular 
weight of 240 kDa. 
The gene was initially designated ORPl (oxygen-regulated photoreceptor 
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protein-1) because its expression was reproducibly altered by oxygen level. Then it 
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was found to be mutated in ADRP and was subsequently designated RPl (Pierce et 
al., 1999). As the function of RPl is not yet known, the reason its expression is 
sensitive to retinal oxygen levels is also unknown. 
1.3.1 RPl gene in animals 
The Rpl gene is the mouse homologue of RPl’ which produces an 8.0-kb 
mRNA whose expression is stimulated by retinal hypoxia and suppressed by relative 
retinal hyperoxia. Rpl is expressed in photoreceptor cell bodies and inner segments 
in the retina. The expression of Rpl increases between post-natal days 5 and 7，the 
time during retinal development when photoreceptor outer segments develop in mice 
(Pierce et al., 1999). 
Sullivan et al. (2000) reported an unusual degree of sequence divergence 
among mammalian RPl genes. Genomic DNA containing the entire RPl gene and 
flanking sequences were sequenced from baboon, squirrel monkey and mouse, and 
the genes were compared. At the amino acid level, the mouse and human proteins 
were only 60% identical, compared to the 94% homology of human and mouse 
rhodopsin proteins and the 91% homology of human and mouse peripherin/RDS. 
Amongst primates, the level of homology was also not as high as expected. The 
results revealed a surprising amount of sequence divergence, an unusual occurrence 
in a presumably critical retinal protein. 
1.3.2 Mutations in RPl 
< Defects in this gene have been reported to cause 5-10% of ADRP (Pierce et 
al., 1999; Sullivan et al , 1999; Bowne et a l , 1999). Mutations in RPl seem to 
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cluster within a 442-nucleotide segment of exon 4. All of them are either nonsense 
or frameshift mutations, leading to a severely truncated protein approximately one-
third the size of wildtype (Bowne et al., 1999). Furthermore, about 58% of these 
RPl mutations are either the Arg677ter or 2280-2284del mutations. The nonsense 
mutation at codon 677 is present in approximately 3% of cases of ADRP in North 
America (Pierce et al , 1999; Sullivan et al., 1999; Bowne et al.，1999; Guillonneau 
et al., 1999). This makes it the third most common ADRP mutation in Caucasians 
after the RHO mutations Pro23His (12%) and Pro347Leu (5%) (Sharma et al.，1999; 
Pierce et al , 1999). There has been no report on sequence alterations in RPl in 
Japanese RP patients. 
1.3.3 Phenotypes & frequencies of RPl mutations 
Although each of the known mutations results in a similarly shortened RPl 
protein, the phenotype of the affected individuals varies greatly. Some families have 
mild disease with late onset and slow progression, while others have more severe 
disease with onset in the teens followed by rapid vision loss. This variation also 
occurs among families with the same mutation, and even among individuals in the 
same family, with several instances of non-penetrance (Bowne et al., 1999; Field et 
al., 1982; Heckenlively et al , 1982). In a linkage-based study of 32 large (>11 
meioses) ADRP pedigrees (Ingleheam et al , 1998b), mutations in RPl were 
reported to cause 3% of the cases. The penetrance was 95% compared to 100% in 
RHO. The age of onset was variable. Their phenotype was confined to type 2 or 
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'R'-type of ADRP. It is possible that the haplotypes of the polymorphic amino acid 
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variants, either in cis or in trans with the disease allele, or other genetic or 
environmental factors, may influence the clinical manifestations of RPl mutations 
(Bowne et al., 1999; Pierce et al., 1999). 
1.4 Mutation Pattern of RHO & RPl in Chinese 
There is one report in the literature regarding mutations of RHO in Chinese 
patients with autosomal dominant RP (Guan et al., 1998). Fifty-seven patients from 
38 families with ADRP and 60 normal controls were recruited from eastern China. 
Point mutations at codon 58 and codon 347 were detected by restriction 
endonuclease digestion of exon 1 and 5 after amplification by polymerase chain 
reaction (PCR). Four patients from one family were found to have a mutation at the 
second nucleotide of codon 58, and 6 patients from two families were found to have 
a mutation at codon 347. Their conclusion was that molecular genetic heterogeneity 
exists within ADRP, and some subtypes of ADRP are caused by point mutations in 
the RHO. 
To date, no report of sequence alterations in RPl in Chinese RP patients has 
been published, and there has been no described screening for sequence alterations 
in the entire RHO and RPl genes in Chinese. 
1.5 Methods for Detecting Mutations in RHO and RPl 
< 
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The most commonly used strategy for detecting single-base mutations in large 
and complex genes is to amplify sequences of genes of interest by polymerase chain 
reaction (PGR), scan the PGR products for the presence of mutations by a rapid 
procedure, and then sequence the PGR products that were positive by the scanning 
technique. The scanning techniques most commonly used for PGR products are 
single-strand conformation polymorphism (SSCP，Orita et al., 1989)，enzymatic or 
chemical cleavage of mismatched base pairs (Cotton et al., 1993; Youil et al., 1995), 
and differentia丨 unfolding of homoduplexes and heteroduplexes by denaturing 
gradient gel electrophoresis (DGGE, Myers et al.，1987; Sheffield et a l , 1989). 
However, SSCP is not reliable with fragments of greater than about 200 bp, 
and the sensitivity is estimated to range from about 60% to 95% (Cotton et al.，1993； 
Grompe et al., 1993; Eng et al., 1997; Nollau et al., 1997; Orita et a l , 1989). DGGE 
is highly sensitive, but it requires the use of GC clamps in one of the primers for 
each PGR product and a considerable effort to optimize conditions for analysis of a 
given gene (Myers et al., 1987; Sheffield et al., 1989; Ritvaniemi et al., 1993; 
Ritvaniemi et al.，1995). 
Conformation sensitive gel electrophoresis is a relatively simple but reliable 
procedure for the scanning of complex genes for the presence of single-base and 
larger base mismatches in DNA (Ganguly et al., 1993; Korkko et al., 1998; Hinks et 
al.，1999; Lam et al., 2000). The assay was based on the assumption that mildly 
denaturing solvents in an appropriate buffer can accentuate the conformational 
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changes produced by single-base mismatches in double-stranded DNA and thereby 
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increase the differential migration in electrophoretic gels of heteroduplexes and 
homoduplexes. It has the advantage over other methods for scanning PCR products 
in that it is simple, requires no special preparation of PCR products, has a large 
capacity, and does not use radioactivity. Ganguly et al (1993) used a panel of 58 
previously identified mutations in six different genes when first developing CSGE 
and reported a detection rate of 86%. More recently, Korkko et al (1998) detected 
all of 76 previously identified single base changes in collagen genes. Markoff et al 
(1998) analysed the BRCAl gene by SSCP and CSGE in 20 breast cancer patients, 
and were able to detect 12 sequence alterations. Of those, all were detected by 
CSGE and eight of them were also shown by SSCP. They concluded that CSGE 
turned out to be the more sensitive technique in their assay. Hinks et al (1999) also 
detected all the mutations in 21 patients with haemophilia B, demonstrating the 
efficacy of CSGE and suggesting that this technique can be used routinely for 
mutation analysis. 
1.6 Management of RP 
With few exceptions, such as Refsum disease, there is no treatment for 
almost all forms of RP. Some symptomatic relief may be derived from cataract 
extraction (Newsome et al., 1986) and carbonic anhydrase inhibition if there is 
macular edema (Cox et al” 1988). Vitamin A supplementation may slow the 
progression although this has been the subject of controversy since clinical outcomes 
‘ are inconsistent (Berson et a l , 1993; Massof et a l , 1993). Although there is no 
treatment by which the primary disorder can be manipulated, the patient can expect 
2 0 
a reasonable account of visual prognosis, accurate genetic counseling, and support 
for rehabilitation. 
Researchers around the world are working on different potential therapeutic 
approaches to the problem. Current strategies for RP therapy include transplantation 
of normal photoreceptors and RPE cells, however without convincing evidence of 
improved human vision (Bok, 1993; Bok et al., 1993; Milam, 1993; Sahel et al., 
1996). Intravitreal injection of neurotrophic factors, such as brain derived 
neurotrophic factor, nerve growth factor and the ciliary neurotrophic factor, that 
prolong photoreceptor survival (Faktorovich et al.，1990; Steinberg, 1994; Unoki et 
al” 1994; Perry et al., 1995; Lin et al., 1997) is an alternative therapeutic approach. 
Unfortunately, the effect of the neurotrophic factors is relatively short lived, lasting 
only about a month in animals (La Vail et al., 1992; 1998). Biological and 
biochemical slow delivery systems are being developed that may overcome the 
problems (Maysinger et al” 1996). 
Gene therapy has been carried out by delivery to mutant photoreceptors and 
RPE cells of corrective genes in viral vectors, such as the replication defective 
herpes simplex virus, the replication defective adenovirus, adeno-associated virus 
and retrovirus. Each has advantages and disadvantages (Zack, 1993; Li et al” 1994; 
Ali et al., 1996; Bennett et al., 1996). However, even though it may be possible to 
introduce a copy of the normal gene into the photoreceptors, thereby increasing the 
quantity of the normal functional protein in the cells, this may not be enough to halt 
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the disease process. In the case of dominant rhodopsin mutations, there is already a 
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normal gene and at least some normal gene product, but this is unable to overcome 
the damaging effects of the mutated gene. It is also possible that the delicate 
internal milieu of the photoreceptor cells may not be able to cope with the excessive 
protein production caused by the additional gene. It is only very recently that the 
techniques for manipulation of the endogenous gene expression have become 
available. This technology could be of potential use for autosomal dominant 
diseases, and extensive research is being done in this area. Ribozymes, or RNA 
enzymes, are catalytic RNA molecules that can cleave specific RNA target 
sequences, resulting in reduced expression of the target gene (Drenser et al” 1998; 
O'Neill et al., 2000). The rescue of the photoreceptor cells by the expression of 
ribozyme in a transgenic rat model of ADRP has been demonstrated (Lewin et al., 
1998). Given the efficiency of the ribozymes evaluated in the study, they should be 
valuable in the development of therapeutic approaches for inherited photoreceptor 
degenerations such as ADRP. 
Currently the only treatment for RP patients is administration of vitamin A 
(Sharma et al., 1999). Oral vitamin A supplementation was reported to slow the rate 
of retinal degeneration in adult patients with the common forms of retinitis 
pigmentosa in a randomized, controlled, double-masked trial (Berson et al.，1993). 
This conclusion was based on measuring the rate of ERG amplitude decline. To test 
and correlate the effects of such therapy with the genotype of the disease and to 
discover what type of patient would be the best candidate for vitamin A therapy, 
‘ further research has been done on two murine models of RP (Li et a l , 1998). 
Transgenic mice with the ThrlTMet mutation (class II mutation in RHO) and mice 
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with the P347S mutation (class I) of the RHO were fed a diet containing either a 
normal or a higher amount of vitamin A. The selection of the class I and class II 
mutants for comparison was based on the second objective of the study, to test the 
hypothesis that class II mutants are more likely to respond to vitamin A 
supplementation than are class I mutants. Based on measuring the rate of ERG 
amplitude decline and histologic evaluation, they concluded that vitamin A 
supplementation can confer therapeutic benefit in the case of class II RHO mutations 
but not in the case of class I by stabilizing mutant opsins through increased 
availability of the chromophore. 
< 
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Table 1-1. Genes and loci identified in retinitis pigmentosa* 












ARRP RPE65 Ip 
ABCR Ip 
RHO 3q 
P-Subunit cGMPPDE 4p 
a-Subunit cGMP PDE 5q 
cGMP-gated channnel 4p 
TULPl 6p 
CralBP 15q 
XLRP RPGR Xp 
RP2 Xp 
RP6 Xp 
Digenic RP ROMl  





Figure 1-1. A typical fundus photo of retinitis pigmentosa. Notice the attenuated 
arterioles, bone-spicule pigmentation (mostly paravenular and 
midperipheral), and waxy pallor of the optic disc 
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Figure 1-2. Molecule of rhodopsin. It consists of 7 transmembrane domains with 
the carboxyl-terminal in the cytoplasmic side and amino-terminal in the 
intradiscal space or extracellular surface. The residues in purple are 
some of the mutation sites. The green spots indicate phosphorylation 
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Figure 1-3. Schematic diagram of a retinal rod cell. Disks are formed by the 
evagination of the plasma membrane at the junction between the 
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Figure 1-4. The visual transduction cascade. 
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Figure 1-5. Gene structure of RHO. The coding region is interrupted by four 
introns, i.e., there are five exons. The mRNA is 1,047 bp long and 
codes for 348 amino acids 
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Figure 1-6. Gene structure of RPL This big gene (14,636 bp) consists of four 
exons，three of which (exon2-4) contain coding sequence. All disease-
causing mutations and polymorphic sites reported are in exon 4. 
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Chapter 2 Objectives 
Retinitis pigmentosa is the most frequent cause of genetic blindness in 
adulthood. Mutations found in RHO account for 25% of ADRP and 10% of all RP, 
and represent the most common known cause of the disease. RPl was discovered in 
1999. Its mutations cause at least 7% of ADRP, and approximately 3% of all RP 
cases in North America, more than any other identified gene besides RHO. 
However, the function of RPl is unclear and no studies have yet reported RPl 
mutations in non-Caucasians. This thesis attempts to: 
1. Discover novel mutations and estimate the prevalence of RHO and RPl 
mutations among Chinese RP patients. 
2. Discover sequence alterations in RPl that might indicate the function of the 
protein. 
3. Assess the diagnostic value of RHO and RPl mutations for RP and provide 
genetic consultations. 
4. Initiate a genetic database of RP in Hong Kong. 
< 
3 1 
Chapter 3 Methodology 
3.1 Study Subjects 
RP patients 
RP patients from 104 separate families were recruited from the Eye Clinic of the 
Prince of Wales Hospital, and the University Eye Centre of the Hong Kong Eye 
Hospital. 
Family members of RP patients 
First-degree and second-degree relatives of the RP patients were also recruited for 
study. 
Control individuals 
Control individuals were recruited from Chinese volunteers aged above 60 years 
with no personal or family history of RP or other kind of retinal degeneration. 
Venous blood samples were collected from 190 unrelated controls. 
Informed consent was obtained from all study subjects. The study protocol has 
been approved by the Ethics Committee for Human Research, the Chinese 
University of Hong Kong. 
3.2 Clinical Data Sheet 
< 
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Diagnostic criteria of RP 
In making a diagnosis, all patients had fundal examination, visual field and 
electrophysiology tests. Clinical data were collected through interviews and hospital 
records. Different approaches for classifying and subtyping are used in primary RP: 
fundus pattern, inheritance pattern, electroretinogram (ERG), and visual field. Since 
many retinal diseases may have similar presentations, it was necessary to observe 
the clinical course over many years, to examine affected and unaffected family 
members and to order tests to exclude pseudo-RP and to confirm secondary RP in 
order to finalize the diagnosis. 
History 
Nightblindness, subjective with a drop in visual acuity (VA), subjective with a 
constriction of visual field (VF) and the age of onset 
Family history of RP (a pedigree was drawn for each patient) 
Any systemic presentation suggestive for pseudo RP 
Secondary RP (deafness, ataxia, mental challenge, obesity, Polydactyly, growth 
retardation, muscle wasting, CNS problem, or others) 
Examination in both eyes 
VA (unaided and pinhole) 
Intraocular pressure (lOP) 
Slit lamp examination to detect status of lens (normal, cataract, pseudophakia, 
aphakia) and vitreal changes (cells or syneresis) 
< 
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Pupillary dilation and fundal examination were performed with indirect 
ophthalmoscopy to detect: 
- M a c u l a r changes 
- O p t i c disc (cup/disc ratio, any waxy pallor, optic atrophy, temporal pallor, or 
drusen) 
- R e t i n a (any RPE mottling, bone-spicules, attenuated vessel, atrophic RPE and 
underlying sclerosed choroidal vessels 
Visual field (Humphrey automated 30-2) for all patients. 
Electroretinogram for all patients. 
Fundal photos for all patients. 
Diagnosis 
Morphological subtype; 
- C l a s s i c a l RP 
- M o t h - e a t e n or salt-and-pepper only 
- R e t i n i t i s pigmentosa sine pigmento (early RP without fundus pigmentary 
changes) 
- S e c t o r RP (retinal atrophy seen in only one part of the fundus) 
- P r e s e r v e d para-arteriolar RPE (PPRPE) 
Family history of RP: 
- " S i m p l e x " when there is only one known affected member in a family 
, - " M u l t i p l e x " if siblings are also affected 
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Hereditary pattern: 
- N o t yet clarified 
- Autosomal dominant 
- Autosomal recessive 
- X - l i n k e d recessive 
Secondary RP/ Specific syndrome 
- U s h e r syndrome 
- R e f s u m disease 
- B a r d e t - B i e d l syndrome 
- O t h e r s 
3.3 Chemicals, Reagents, and Kits 
Agarose, ethidium bromide, 40% acrylamide, formamide, ethylene glycol, 
1,4-bis (acryloyl) piperazine, ammonium persulfate (APS), N � N , N’�N'-tetramethyl 
ethylenediamine (TEMED), ethylenediamine-tetraacetate di-sodium salt (EDTA), 
tris base, taurine, ammonium acetate, bromophenol blue, ethanol (absolute), 
hydrochloric acid, magnesium chloride, dATP, dCTP, dGTP, dTTP, sodium 
hydroxide, and hydrochloric acid. All were purchased from SIGMA, St. Louis, MO, 
USA. The 50 bp and 1 Kb DNA Ladder were obtained from GIBCO BRL as DNA 
markers. 
Reagent Kits 
QIAamp® Blood Kit (Qiagen, Hilden, Germany) 
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Microspin™ S-300 HR Columns for DNA purification (Pharmacia Biotech, Det 
Norske Veitas, Denmark) 
dRhodamine Dye Terminator FS Cycle Sequencing Ready Reaction Kit (PE Applied 
Biosystems, Foster City, CA, USA) 
3.4 Solutions and Buffers 
lOX PCR buffer: 20mM Tris-HCl (pH 8.4)，50mM KCl 
Agarose gel loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol FF and 
30% glycerol 
Ethanol: 70% v/v 
Ethidium bromide: 0.25 |Lig/ml 
SYBR® Gold solution: 1 ^1/7.5 ml, Molecular Probes, Eugene, Oregon, USA 
Deionized formamide loading buffer: 80% formamide, 4.2 mM EDTA, with 8.3 
mg/ml blue dextran 
Proteinase K: 10 mg/ml, in 1% SDS and 2 mM EDTA 
50X TAE buffer: 2M Tris-Acetate, 50 mM EDTA, pH 8.3 
lOX TBE buffer: 1.0 M Tris, 0.9 M Boric acid, 10 mM EDTA, pH 8.4 
20X TTE buffer: 1.8 M Tris base, 4mM EDTA, 0.6 M taurine, pH 9.0 
Nuclei lysis buffer: 50 mM NaOH, 1 M TrisHCl (pH 8.0) 
Longranger™ gel solution (50% stock, derived from acrylamide; FMC BioProducts, 
Rockland, ME, USA) 
GENE PAGE PLUS 5.25% 6 M UREA (blends of acrylamide, cross-linker, and 
urea; AMRESCO, Solon, Ohio, USA) 
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3.5 Enzymes 
Proteinase K for DNA extraction (Qiagen, Hilden, Germany) 
Taq DNA polymerase (GIBCO BRL, Life Technologies, Gaithersburg, MD, USA) 
Maell restriction endonucleases (Boehringer Mannheim, Mannheim, Germany) 
Exonuclease I (Exol) and Shrimp alkaline phosphatase (SAP) (Amersham Life 
Science, Ohio, USA) 
3.6 Equipment 
GeneAmp® PCR System 9700 (PE Biosystems, Foster City，CA, USA) 
ABI 377-XL automated DNA sequencer (PE Applied Biosystems, Foster City, CA’ 
USA) 
Model S2001 sequencing gel electrophoresis apparatus, air-cooled system (Life 
Technologies Ltd., Inchinnan Business Park, Scotland) 
Genequant pro RNA/DNA Calculator (Pharmacia Biotech, Cambridge Science Park, 
England) 
Mupid-21, mini-gel electrophoresis unit (Cosmo Bio Co.，LTD., Tokyo, Japan) 
PowerPac 3000, 220/240 V (Bio Rad Laboratories, Hercules，CA, USA) 
UV-Transilluminator at 309 nm (UVP Inc., CA, USA) 
Mineralight® Lamp Model UVGL-15 (Upland, CA, USA) 
Polaroid MP4+ Instant Camera System (Polaroid, Herfordshire, England) 
Fotodyne 3-3502 (Hartland, WI，USA) 
Gel Doc 2000 Video Gel Documentation System-Mac, 220/240 V (Bio Rad 
Laboratories, Hercules, CA,USA) 
Calomel pH Electrodes, model 7102SC (Orion Research, Inc., Beverly, MA, USA) 
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3.7 Software 
PrimerExpress™1.0: applications-based primer design software (PE Applied 
Biosystems, Foster City, CA, USA) 
Free primers design software online: www.williamstone.com/primers/ 
ABI 377-XL automated DNA sequencing analysis (PE Applied Biosystems, Foster 
City, CA, USA) 
FaturaTM (PE Applied Biosystems, Foster City, CA, USA) 
Sequence Navigator™ (PE Applied Biosystems, Foster City, CA, USA) 
Quantity One® 4.0.3 (PE Applied Biosystems, Foster City, CA, USA) 
3.8 Oligonucleotide Primers for PGR, CSGE and Sequencing 
Oligonucleotide primers for PGR, CSGE and sequencing analysis of the 
RHO and RPl genes are listed in Table 1 and 2，respectively. They were designed 
to cover all the coding sequences and splice sites in the above two genes, based on 
genomic DNA sequences in GenBank, accession numbers U49742, K02281, and 
AF143223. Computer programs used were PrimerExpress™1.0 (PE Applied 
Biosystems, Foster City, CA, USA) and free primer design software 
(www.williamstone.com/primers/). Figure 3-1 shows an example of primer analysis 
using the above software. The primers were purchased from GIBCO BRL. 
3.9 DNA Extraction 
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3.9.1 DNA extraction from blood samples 
Genomic DNA was extracted from EDTA-blood using a QIAmp Blood Kit 
(Qiagen, Hilden, Germany) according to the manufacturer's Blood and Body Fluid 
Spin Protocol. Two hundred microlitres of EDTA blood was resuspended in 20 |j.l 
Proteinase K and 200 |il Buffer AL, then mixed by pulse-vortexing for 15 sec and 
incubated at 56°C for 10 min. Two hundred microlitres 100% ethanol was added 
and mixed again by vortexing. The mixture was applied to the QIAamp spin column 
and centrifuged at 8,000 rpm for 1 min. The spin column was then washed twice 
with 500 |Lil of Buffer AW. The DNA was eluted from the column with 150 |il 
Buffer AE. One microlitre was used for PCR. 
3.9.2 DNA extraction from buccal swab 
Some patients had difficulties in giving blood, so a buccal swab was taken using 
CytoSoftTMBrush • 1 CP-5B (Medical Packaging Corp., Camarillo, CA USA). The 
brush was then submerged in 600 \i\ 50mM NaOH and agitated in a 1.5 ml tube so 
that the cells on the brush were dispersed into the solution. After incubating at 95°C 
for 5 min., the brush was removed and 60 |li1 1 M TrisHCl (pH 8.0) was added for 
neutralization. One |il of the mixture containing genomic DNA was used for PCR. 
3.9.3 DNA Quantitation 
The extracted DNA was diluted 1:50 (3 |il DNA + 147 |il water), and the 
absorbence at wavelengths of 260 nm and 280 nm were measured on the Genequant 
pro RNA/DNA Calculator (Pharmacia Biotech, Cambridge Science Park, England). 
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The reading at 260 nm allows calculation of the concentration of nucleic acid in the 
sample. The ratio between the readings at 260 nm and 280 nm provides an estimate 
of the purity of the nucleic acid. Pure preparations of DNA have a ratio of 1.8. In 
this study, the ratios of the extracted DNA from either blood samples or buccal 
swabs were between 1.5-1.8. The concentrations of extracted DNA were 30-100 
ng/|ll. 
3.10 Polymerase Chain Reaction (PGR) 
3.10.1 Amplification oiRHO 
Fragments of the RHO gene sequence were amplified by PGR in a total 
volume of 25 |iL, containing 20 mM Tris-HCl (pH 8.4)，50 mM KCl, 1.5 mM or 2.0 
mM (for Exon 2) MgCh, 0.5 |iM each of sense and antisense primers, 0.2 |iM dNTP 
mix, lU Taq DNA polymerase (GIBCO BRL, Life Technologies, USA) and 1 |iL 
extracted genomic DNA. The PGR conditions: denaturing of the DNA at 94°C for 4 
minutes, then cycling 35 times at the following temperatures: 94�C，62°C or 6 0 � C 
(for Exon 2) and 72°C each for 50 seconds. The cycling was followed by an 
additional 3-minute extension step at 72°C. A total of six amplicons were carried 
out for RHO gene analysis. 
3.10.2 Amplification oiRPl 
There were 26 amplicons designed for the RPl gene. The PGR conditions 
for each amplicon are shown in Table 2. 
< 
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3.11 Gel Electrophoresis 
3.11.1 Agarose gel electrophoresis 
A 2% w/v agarose gel was prepared in 0.5X TAE buffer containing 0.5 
M-g/ml ethidium bromide. Four )LIL of PGR product or 10 |IL of restriction enzyme 
digested DNA was mixed with 2 |LIL 6X loading dye containing 0.25% bromophenol 
blue, 0.25% xylene cyanol FF, and 30% glycerol. Electrophoresis was performed in 
a horizontal electrophoretic tank containing a pre-set agarose gel immersed in 0.5X 
TAE at lOOV for 15 to 20 minutes. The bands were detected on an UV 
transilluminator at 309nm. Photographs were taken either with a Gel Doc 2000 (Bio 
Rad Laboratories, Hercules, CA, USA) and analyzed using the software Quantity 
One® 4.0.3 (PE Applied Biosystems, Foster City, CA, USA), or Polaroid MP4+ 
Instant Camera System (Polaroid, Herfordshire, England) using Polaroid 667 Black 
and White (BAV) films. 
3.11.2 Conformation sensitive gel electrophoresis (CSGE) 
Three |LI1 PGR product was mixed with 2 |iL loading dye containing 0.25% 
bromophenol blue, 0.25% xylene cyanol FF and 30% glycerol. The mixture was 
denatured at 94�C for 5 minutes and reannealed at room temperature for 1 hour, then 
was electrophoresed on a 15% polyacrylamide gel (Table 3-5). The gel was run at 
40 W 7-10.5 hours in 0.5X TTE using a PowerPac 3000, 220/240 V (Bio Rad 
Laboratories, Hercules, CA, USA) with a Model S2001 Sequencing Gel 
‘ Electrophoresis Apparatus, Air-cooled System (Life Technologies Ltd., Inchinnan 
Business Park, Scotland). 
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After electrophoresis, the gel was transferred to a Whatmann 3-mm blotting 
paper (Maidstone, England) and stained by overlaying 20 mL IX SYBR® Gold 
solution (Molecular Probes, Eugene, Oregon, USA) for 10 min. The bands were 
visualized by a Mineralight® Lamp Model UVGL-15 (Upland, CA, USA) and were 
cut out with the blotting paper. The gel was then photographed using a Bio-Rad Gel 
Doc 2000 (Bio-Rad Laboratories, Hercules, CA) and analyzed by the software 
Quantity One® 4.0.3 (PE Applied Biosystems, Foster City, CA, USA). 
3.11.3 DNA sequencing 
Samples that showed a heteroduplex pattern in CSGE analysis were subject 
to cycle sequencing. Five |il of each PCR product was treated with 1.5U of 
Exonuclease I (Exol) and 0.5U of Shrimp alkaline phosphatase (SAP) (Amersham 
Life Science, Ohio, USA) at 37°C for 1 hour in a total volume of 7 |il to remove 
excess primers and dephosphorylate excess dNTPs. The enzymes were then 
inactivated by incubation at 72 °C for 15 minutes. For cycle sequencing reactions, 
2.5 III of this treated DNA sample was used. 
The purified DNA products were subject to cycle sequencing using the 
dRhodamine Dye Terminator FS Cycle Sequencing Ready Reaction Kit (PE Applied 
Biosystems, Foster City, CA, USA) in a total volume of 5 |LI1. After the sequencing 
reaction was completed, the DNA samples were precipitated by adding 3 |LI1 7.5M 
ammonium acetate and 30 |il 100% ethanol and incubating at -80°C for 15 minutes. 
After centrifugation at 12,000g for 15 minutes and the supernatant was aspirated, the 
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sample was washed with 70% ethanol once. The DNA pellets were dried in a 
thermal cycler by heating 45 seconds at 94°C with the tube lids open. The dried 
samples were resuspended in 1 |iL deionized formamide loading buffer (80% 
formamide, 4.2 mM EDTA, with 8.3 mg/ml blue dextran). All the samples were 
analyzed on 4% acrylamide gels containing 6M urea and IX TBE solution (For 
compositions of the gels, see Table 3-6)，using a PE Applied Biosystems ABI 377-
XL automated DNA sequencer. A 0.2-mm thick 64-well shark's teeth comb was 
used to load 0.75 |LIL of the resuspended samples. 
Forward and reverse primers were used respectively in all the samples 
analyzed by direct sequencing to obtain definite sequencing results, which were 
analyzed using software including ABI 377-XL automated DNA Sequencing 
A n a l y s i s™�F a c t u r a ™ and Sequence N a v i g a t o r ™ (PE Applied Biosystems, Foster 
City, CA, USA). Sequence variations expected to affect protein sequence or 
expression were evaluated further by direct genomic sequencing for the presence of 
the variant sequences in the DNA samples from relatives of the respective patients. 
3.12 Statistical methods 
Chi-square tests were used to determine significance of association of sequence 
alterations with disease. Confidence limits for proportions (Zar, 1984) were 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3-3. Components of one CSGE gel 
15% polyacrylamide gel 
20X TTE 2.5 ml 
40% acrylamide 37.5 ml 
1,4-Bis (acryloyl) piperazine 0.15 g in 1 ml deionized water 
(prepared fresh) 
Formamide 15 ml 
Ethylene glycol 10 ml 
Deionized water 33 ml 
10% APS 1 ml 
TEMED 70 |j1 
Total volume 100 ml 
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Table 3-4. Components of one sequencing gel 
4% acrylamide gel 
Urea 9 g 
50% L o n g r a n g e r ™ gel solution 2.5 ml 
(FMC BioProducts, Rockland, ME, USA) 
Deionized water 12.5 ml 
lOX TBE 2.5 ml 
Add deionized water to 25 ml 
As an alternative to the above, use 25 ml of Gene page plus 5.25% 6 M urea 
(AMRESCO, Solon, Ohio, USA) 
(After degas) 
10% APS 125 Ml 







A - 8 (36.36%) C -4 (l8.18%) A - 3 (13.64%) C -4 (18.18%) 
G - 4 (18.18%) T -6 (27.27%) G - 7 (31.82%) T -8 (36.36%) 
N -0 (0.00%) N -0 (0.00%) 
Coordinates: 73 .. 94 Coordinates: 468 .. 447 
Tm 
Nearest Neighbor T m (standard): 
%GC Method Tm: 
Tm 
57.49°C Nearest Neighbor T m (standard): 
49.25°C %GC Method T m: 







GCCTTAGAAA AGAATGATTC TCAGAATTTA CCAATATATC CTTCTGAAGA TGATATTGAG 
I 1111111111 1111111 11 I I I11 I I 1111 111111 I I11 1111111111 11 111 I11 11 
CGGAATCTTT TCTTACTAAG AGTCTTAAAT GGTTATATAG GAAGACTTCT ACTATAACTC 
AAATCAATTA TTTTTAATCA AGACGGCACT ATGACAGTTG AGATGAAAGT TCGATTCAGA 
611111111111 1111111111 1111111111 1111111111 1111111111 1111111111 
TTTAGTTAAT AAAAATTAGT TCTGCCGTGA TACTGTCAAC TCTACTTTCA AGCTAAGTCT 
ATAAAAGAGG AAGAAACCAT AAAATGGACA ACTACTGTCA GTAAAACTGG TCCTTCTAAT 
1211111111111 1111111111 1111111111 1111111111 1111111111 1111111111 
TATTTTCTCC TTCTTTGGTA TTTTACCTGT TGATGACAGT CATTTTGACC AGGAAGATTA 
AATGATGAAA AGAGTGAGAT GAGTTTTCCA GGAAGAACAG AAAGTCGATC ATCTGGTTTA 
181 1111111111 1111111111 1111111111 1111111111 1111111111 1111111111 
TTACTACTTT TCTCACTCTA CTCAAAAGGT CCTTCTTGTC TTTCAGCTAG TAGACCAAAT 
AAGCTTGCAG CATGTTCATT CTCTGCAGAT GTGTCACCTA TGGAGCGAAG CAGTAATCAA 
2411111111111 1111111111 1111111111 1111111111 1111111111 1111111111 
TTCGAACGTC GTACAAGTAA GAGACGTCTA CACAGTGGAT ACCTCGCTTC GTCATTAGTT 
GAGGGCAGTT TGGCAGAGGA GATAAACATT CAAATGACAG ATCAAGTGGC TGAAACTTGC 
3011111111111 1111111111 1111111111 11 i 1111111 1111111111 1111111111 
CTCCCGTCAA ACCGTCTCCT CTATTTGTAA GTTTACTGTC TAGTTCACCG ACTTTGAACG 
AGTTCTGCTA GTTGGGAGAA TGCTACTGTG GACACAGATA TCATCCAGGG AACTCAAGAC 
361 1111111111 1111111111 1111111111 1111111111 1111111111 1111111111 
TCAAGACGAT CAACCCTCTT ACGATGACAC CTGTGTCTAT AGTAGGTCCC TTGAGTTCTG 
CAAGCAAAGC ATCGTTTTTA TAGGCCCCCT ACACCTGGAC TAAGAAGAGT GAGACAAAAG 
4211111111111 1111111111 1111111111 1111111111 1111111111 1111111111 




Forward Primer Reverse Primer 
Hairpin Analysis 
Primers may fold and anneal against themselves. A likely folding scenario is displayed below. 
- - TTTAATCAAGA 3' 5' - -- ---TCTTCTTAGTCC 3' 
I I I I I 
AGTAT- CACGGC 5' 3' GGGATGTGGA- - 5' 
Primer-Dimer Analysis 
Primers may anneal with other copies of themselves. Below is a candidate alignment. 
TTTAATCAAGACGGCACTATGA 3' 5 ' TCTTCTTAGTCCAGGTGTAGGG 3' 
I I I 11 I 11 I I 11 11 11 I 
AG- TA- TCACGGCAGAACTAATTT 5' 3' - GGGA- T- GTGGACCTGATTCTTCT 5' 
Primer Pair Similarity 
Forward primers may anneal with with reverse primers. A likely alignment is shown below. 
---------TTTAATCAAGACGGCACTATGA 3' 
I I 
TCTTCTTAGTCCAG--GTGTAGG --- - G 5' 
-






Chapter 4 Results 
4.1 Study Subjects (Table 4-1) 
4.1.1 RP index patients 
There were 104 index patients, including 47 males and 57 females. All of 
them had typical history and clinical features of RP. In quite a few cases there was 
little or no family structure to provide clues as to the genetic classification of the 
patients. 
Two of the patients had deafness as well as RP and were suspected to have 
Usher syndrome. Another patient with nystagmus and profound poor vision since 
birth was suspected to have Leber's congenital amaurosis (LCA). One blood sample 
from Stargardt's disease was also screened in RHO and RPL 
4.1.2 Family members of index patients 
When a sequence alteration detected in an index patient was suspected to be 
a mutation, DNA was extracted from available blood samples of family members of 
the patient and screened for the sequence alteration. The family members could be 
RP or non-RP. Family members of six index patients were analyzed. 
4.1.3 Controls 
190 unrelated control individuals above 60 years old without personal or 
‘ family history of RP or other kinds of retinal degeneration were screened for 
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sequence alterations in all coding exons and splice sites of RHO and RPl. Three 
benign variants were found in RHO and eight were found in RPL 
4.2 Genetic subtypes of RP in our study (Table 4-2) 
Based on the available family histories, the above RP index patients were 
roughly divided into four subtypes: simplex, autosomal dominant, autosomal 
recessive, and X-linked RP. Patients with at least one affected parent, or affected 
child were calculated as ADRP; patients with affected siblings but both parents 
normal were calculated as ARRP; male patients with affected male relatives on the 
maternal side were XLRP; patients with no known affected relatives were simplex 
cases. 
4.3 PCR 
Thirty-three PCR protocols were established for screening and identification 
of RHO and RPl mutations. Of these, 7 were for RHO and 26 were for RPL The 
PCR protocols were optimized for the magnesium concentration in the PCR 
substrate and the annealing temperature in PCR. A titration of between 1.0 to 2.0 
mM magnesium (in 0.5 mM increments) was performed to determine the best 
concentration for each set of PCR reaction conditions. The melting temperature 
(Tm) was obtained by using Primer Express an applications-based primer design 
‘ program. Annealing temperature (Ta) was first tried 2 to 3 °C lower than the Tm, 
and a series of control reactions were set up to determine the annealing temperatures 
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that gave optimal results for a given amplification reaction. The range of Ta was 
from 54 to 68 (Table 3-1,2). 
4.4 Conformation Sensitive Gel Electrophoresis (CSGE) 
A CSGE protocol was established for detecting heterozygous status of RHO 
and RPL To improve the sensitivity of CSGE, PCR products were designed ranging 
from 260 bps to 493 bps so as to have at least 50 bps unimportant sequence at each 
end. In addition, to obtain the best separations between homoduplexes and 
heteroduplexes by CSGE, we used the electrophoretic conditions of 40 W for 8 hrs 
for 300 bp DNA fragments and proportionally longer times for longer fragments. In 
one CSGE, 96 PCR products were divided into three batches and 3 pi was loaded in 
each well. In our study, 23 nucleotide substitutions and one 1-bp deletion causing a 
shift of the reading frame were detected by this simple method, with a double-band 
pattern in the gel (Figure 4-1). 
4.5 Direct DNA Sequencing 
The heteroduplexes detected in CSGE were further investigated by direct 
sequencing of the PCR products. The standard protocol for direct DNA sequencing 
was modified by reducing the volume of cycle sequencing reagent used by 75% 
without affecting the sequencing quality, so that the running expenditure was 
reduced. Direct sequencing identified 24 sequence alterations, 9 in RHO and 15 in 
RPl. To detect a nucleotide change, software such as ABI 377-XL automated DNA 
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Sequencing Analysis, FacturaTM, and Sequence N a v i g a t o r ™ (PE Applied 
Biosystems, Foster City, CA, USA) were applied. 
4.5.1 Sequence alterations in RHO (Table 4-3) 
5211delC 
This novel mutation is caused by deletion of a "C" after nucleotide 5211 in 
exon 5 of RHO (Figure 4-2,3). It results in a shift in the reading frame, altering the 
last 22 codons thereafter, abolishing the normal stop codon at 349, and causing the 
sequence to run on for another 10 codons before the nearest stop codon, TAG, is 
met. The deletion was revealed on CSGE with double bands implicating differential 
migration of DNA heteroduplex. The mutation was detected in the proband of 
Family A and in her daughter with RPE mottling in the fundi. It was only detected 
in one of 101 index patients but not detected in any of the 190 controls. 
Pro347Leu 
This missense mutation was found in the second-to-last codon, also in exon 
5’ in one of 101 index patients. It is a C > T substitution at nucleotide 5271, 
changing codon 347 from proline (CCG) to leucine (CTG), designated as Pro347Leu 
or P347L (Figure 4-4). The single-base alteration was revealed by CSGE with 
double bands. The index patient in Family B was found to have the above mutation. 
Four children of the index patient were genotyped, and the same mutation was found 
in three of them, who also have RP. None of the 190 controls carried this mutation. 
Ala299Ser 
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This missense change was found in exon 4 in one of the index patients and 
two of the controls. It is a G > T transversion at nucleotide 4293, changing GCC 
(alanine) at codon 299 to TCC (serine) (Figure 4-5). It was revealed by CSGE with 
double bands implicating the heterozygous status of the PGR product. This was the 
only missense change in RHO that could be found in the controls in our study. 
Thr62Thr 
This silent sequence alteration was found in exon 1 in one out of 101 index 
patients. It is a C > T transition at nucleotide 480, changing ACC at codon 62 to 
ACT but not the coding amino acid, threonine. It was also revealed by CSGE with 
double bands implicating a heterozygous status in the amplified DNA sequence. It 
was not detected in 190 controls. 
Leu259Leu 
This is a silent sequence alteration detected in exon 4. The C > T 
substitution at nucleotide position 4175 changes ATC to ATT at codon 259，both 
coding leucine. It was detected in one of 101 index patients on CSGE as a double-
band pattern of heterozygotes. None of the 190 controls had the same sequence 
alteration. 
Thr340Thr 
The last silent sequence alteration detected in RHO is in exon 5 with a G >A 
transition at nucleotide 5251. The codon 340 is changed from ACG to ACA without 
< altering the coding threonine. It was also revealed by CSGE in one out of 101 index 
patients, and was not detected in the controls. 
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Polymorphisms in non-coding nucleotide sequence 
An A > G transition at nucleotide 269 was detected both in one of 101 index 
patients and one of 190 controls in the 5’ untranslated region (UTR). It appeared as 
a double-band pattern in CSGE. 
The other transition of G >A is at nucleotide 5145 in intron 4. It was found 
in 35 index patients and 78 controls (P= 0.29). Sequencing was directly performed 
after PGR in order to detect homozygotes of the sequence change with relatively 
high frequency. 
One C > A transversion was found in 3，UTR with the frequencyies of 
11/101 in index patients and 20/190 in the controls. It was revealed by a double-
band pattern in CSGE. 
4.5.2 Sequence alterations in RPl (Table 4-4) 
One disease-causing mutation and 14 sequence alterations in RPl were 
identified by direct sequencing. All but one sequence alteration were in exon 4. 
They were revealed by a double-band pattern in CSGE. Nine of them are novel (*). 
Because codon 677 in this gene was reported to be a 'hot spot' for mutation in RP!， 
we designed one more primer pair to amplify that site in the gene (forward primer: 
CAAGTGCAATAAGTGCTGGT, reverse primer 
TCCTTTGGTTGCAAGCTGTC). This means the 'hot mutation spot' in RPl has 
been explored twice using differently designed primer pairs. A mutation Arg677ter 
was found in one of the index patients. 
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Arg677ter 
The nonsense mutation was caused by a C > T transition in codon 677. The 
originally coding sequence CGA was changed to TGA, which is a stop codon 
(Figure 4-6). It is designated as Arg677ter or R677X. The mutation was detected in 
one of the RP index patients who also had Fuchs，corneal endothelial dystrophy in 
her right eye. She had an affected mother and elder brother indicating a family with 
ADRP (Family E). However, the DNA samples of them were not available. All the 
other family members of the proband who took part in this study did not have RP 
and were found to be mutation free. 
^Argl933ter 
This novel nonsense sequence change was caused by a C > T transition in 
codon 1933，so that the CGA coding arginine is altered to TGA, a stop codon 
(Figure 4-7). It is designated as Argl933ter or R1933X. It was detected in a patient 
with Stargardt's disease whose blood sample was collected for RP study by mistake, 
and one of the 190 control individuals. The parents and the elder brother of the 
patient with Stargardt's disease were genotyped to look for the same sequence 
alteration although none of them had RP or Stargardt's disease. The father and the 
brother were also found to be carrying Argl933ter in RPl (Family F). 
*Arg249His 
This rare novel sequence alteration was detected in one of the index patients 
and none of the controls in exon 3 of RPl. A transition of G to A caused the CGT 
for arginine (R) in codon 249 to be altered to CAT for histidine (H). Three children 
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of the proband were genotyped. None of them was found to carry this sequence 
alteration although the eldest daughter was also an RP patient. 
*Met479Ile 
This missense sequence alteration was found in codon 479 with a G > T 
transversion, causing ATG coding methionine (M) to be changed to ATT for 
isoleucine (I). It was found in one index patient and none of the controls. The only 
family member available for the study, a 30-year-old son of the index patient, had no 
symptom or sign of RP, and he carried Met479Ile. The proband was a 66-year-old 
female who experienced the onset of symptoms sometime before the age of 61 and 
had visual acuity as good as 20/30 in both eyes with only mild RPE mottling in the 
fundi. 
^Gly706Arg 
This missense sequence alteration is caused by a transversion of G to C in 
codon 706, so that GGT changes to CGT coding arginine instead of glycine. It was 
found in one index patient and one of 190 controls. The four children of the index 
patient had no clinical evidence of RP. Three of them were found to carry the above 
sequence alteration (Family D). 
Arg872His 
This is caused by a G to A transition in codon 872, i. e.’ the CGT coding for 
arginine is changed to CAT for histidine. This sequence alteration was found in 73 
‘ index patients and 130 controls (P= 0.5). 
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Asn985Tyr and Cys2033Tyr 
These two missense sequence alterations seemed to be co-existing in 14 
index patients and 27 controls (P= 0.94). Codon 985 changed from the original 
A AT，coding asparagine, to TAT, coding tyrosine. Codon 2033 changed from TGT, 
coding cysteine, to TAT, coding tyrosine. 
*Glnl008Gln 
This silent sequence alteration was caused by a transition of G to A in codon 
1008, causing CAG > CAA, both coding glutamine. It was found in one of the 
index patients and one of the controls. 
*Glnl063Arg 
An A to G transition in codon 1063 causing CAA > CGA was found in one 
out of 190 controls, but none of 101 index patients. The codon is then coding 
arginine instead of glutamine. 
*Ile2141Met 
This is also a sequence alteration found only in the controls but not in the 
index patients in our study. An A to G transition in codon 2141 changes ATA to 
ATG, coding methionine instead of isoleucine. 
Alal670Thr & Serl691Pro 
These two missense sequence alterations co-existed in 56 out of 101 index 
‘ patients and 106 out of 190 controls (P= 0.96). In CSGE, although they were in the 
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same amplicon, the differential migration appeared as a double-band pattern just like 
that of an amplicon containing only one alteration in the sequence. 
*5880C>T(3' UTR) 
This polymorphism in the 3，UTR was detected in one of the index patients 
and two of the controls. It is a transition of C to T at nucleotide 5880. 
*6014T>A (3，UTR) 
This transversion at nucleotide No. 6014 was detected in one index patient 
and two controls in the 3’ untranslated region of RPl. 
A summary of RHO & RPl disease-causing mutations detected in our study 
subjects is given in Table 4-5. 
4.6 Family Studies 
Family A (5211delC in RHO, Figure 4-8) 
The proband of family A was a 53-year-old female. Her earliest symptom 
was night blindness with an age of onset at about 30. She had a visual acuity (VA) 
of OD 0.5/200 and OS 5/200. The fundi appeared as moth-eaten RP with waxy 
pallored optic discs, RPE mottling, bone-spicule pigments and attenuated vessels. 
She had constricted visual field and her ERG was flat in both scotopic and photopic 
states. The younger daughter, who also carried 521 IdelC in RHO, was 26 years old 
with no symptoms of RP. She had good visual acuity of 20/10 in both eyes, but 
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there was RPE mottling and moderately decreased both rod and cone responses in 
ERG. 
Family B (Pro347Leu in RHO, Figure 4-9) 
The proband of this family was a 55 years old female. Her earliest symptom 
was nightblindness at the age of about 17. She had an onset of acute angle closure 
glaucoma (AACG) in the right eye in the year 1996 and was treated by laser 
peripheral iridotomy using YAG. The visual acuity at that time was OD 18/70 and 
OS 18/50; and she also had constricted visual fields in both eyes. The intraocular 
pressure (lOP) was satisfactorily controlled after laser treatment. However, by the 
end of the year 1999, the visual acuity had dropped in the right eye, to only light 
perceptibility at 2 feet, and in the left eye to 20/70. She was then found to have 
cataracts in both eyes, and more severe in the right eye. She also had pale optic 
discs in both eyes with a cup/disc ratio of 0.8 in the right eye indicating optic nerve 
atrophy probably due to acute angle closure glaucoma, and the normal ratio of 0.2 in 
the left eye. Other fundi appearances were bone-spicule pigments and attenuated 
vessels. 
The Pro347Leu mutation was detected in three children of the proband aged 
33，28 and 17. All three affected had onset of nightblindness at the age of about 17. 
They had visual acuity of 20/30, pink discs, and bone-spicule pigments, constricted 
visual field, and poor overall rod and cone response in ERG in both eyes. The one 
, child spared was the eldest son, with no symptom or sign of RP at the age of 34 
years. 
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Family C (Arg249His in RPl, Figure 4-10) 
The proband was a 52-year-old female with typical symptoms and signs of 
RP. Although her eldest daughter was also an RP patient, she was not carrying the 
same missense sequence alteration. Apparently, Arg249His in RPl did not 
segregate with the disease in this family. 
Family D (Gly706Arg in RPl’ Figure 4-11) 
The proband in this family is a 54-year-old woman. She had visual acuity of 
20/50 (OD) and 20/70 (OS) in 1993，when she was diagnosed RP. Other clinical 
findings were bilateral waxy optic discs and bone-spicule pigments in the four 
quadrants of retina. Four children of hers, with no symptom or clinical finding of 
RP, were genotyped to look for the above missense sequence alteration. Three of 
them had the positive results. 
Family E (Arg677ter in RPl, Figure 4-12) 
The proband in this family was a 47-year-olci female who had symptoms of 
nightblindness, a drop in visual acuity and a constriction of visual field at the age of 
40. Her visual acuity was hand movement in the right eye and 20/200 in the left eye. 
She also had Fuch's corneal dystrophy in the right eye, so the right fundus could not 
be investigated. The left fundus had moth-eaten RP appearance with RPE mottling, 
attenuated vessels and pale optic disc. Her visual fields were constricted and the 
(• 
ERG showed extinguished ‘a’ and 'b' waves in scotopic and photopic states in both 
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eyes. The hereditary pattern in this family indicates autosomal dominant 
transmission. However, the family members who participated in this study were all 
disease free and found not to carry the mutation. 
Family F (Argl933ter in RPl, Figure 4-13) 
The proband was a 10 years old boy with Stargardt's disease, who was the 
youngest member in the family. Genomic DNA of his parents arid elder brother was 
screened for the Argl933ter in RPL The father and the elder brother were found to 
be carriers of the above nonsense sequence change without any symptom or sign of 
RP or Stargardt's disease. 
(• 
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Table 4-1. Subjects 
Subject No. Male Female Age (years) 
RP 101 46 55 5-79 
Usher syndrome 2 1 1 31,39 
Leber's congenital amaurosis 1 0 1 37 
Stargardt's disease 1 1 0 10 
*Family members 23 12 11 5-50 
Controls 190 94 96 >60 
*Family members of index patients with possible mutations in RHO & RPl 
(• 
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Table 4-2. Genetic subtypes of RP in our study 
Simplex ADRP ARRP XLRP 
Our study 71.8% 15.3% 11.7% 1.2% 
Literature 40-55% 15-20% 20-25% 10-15% 
(• 
6 5 
Table 4-3. Sequence alterations identified in RHO in our study 
, . J Frequency Frequency 
Codon Nucleotide Exon in index in References 
change change patients controls  
Dryja et al., 
5' UTR A269G 1 1/101 1/190 1991; Sung et 
al., 1991a 
Thr62Thr ACC480ACT 1 1/101 0/190 Novel 
Leu259Leu ATC4175ATT 4 1/101 0/190 Novel 
Ala299Ser GCC4293TCC 4 1/101 2/190 Novel 
Sung et al , 
1991a. Intron 4 G5145A Intron 4 35/101 78/190 Kawario et al , 
1995 
*From 327 5211delC 5 1/101 0/190 Novel 
Thr340Thr ACG5251ACA 5 1/101 0/190 Novel 
Pro347Leu CCG5271CTG 5 1/101 0/190 Dryja et al.’ 199 
Sung et al., 
1991a. 
3 'UTR C5321A 5 11/101 20/190 ^awa^o et al., 
1995 
*One base pair deletion in codon 327 results in a shift in the reading fame and 
abolished the normal stop codon at 349, resulting in a rhosopsin molecule 10 amino 
acids longer 
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Table 4-4. Sequence alterations identified in RPl in our study 
Codon change Exon Frequency in Frequency in References Codon change t^xon index patients controls  
Arg249His 3 1/101 0/190 Novel 
Met479Ile 4 1/101 0/190 Novel 
Pierce et al , 1999: 
Arg677ter 4 1/101 0/190 Sullivan et al , 1999 
Gly706Arg 4 1/101 1/190 Novel 
Arg872His 4 73/101 130/190 Sullivan et al , 1999 
… … Sullivan et al., 1999; 
Asn985Tyr 4 14/101 27/190 Jacobson et al., 2000 
GlnlOOSGln 4 1/101 1/190 Novel 
Glnl063Arg 4 0/101 1/190 Novel 
Sullivan et al., 1999; Alal670Thr 4 56/101 106/190 jacobson et al , 2000 
, � � � � r ^ A Sullivan et al , 1999; Serl691Pro 4 56/101 106/190 jacobson et al , 2000 
Argl933ter 4 0/101 1/190 Novel 
。 ， S u l l i v a n et al., 1999; 
Cys2033Tyr 4 14/101 27/190 jacobson et al , 2000 
Ile2141Met 4 0/101 1/190 Novel 
5880 O T 4 0/101 2/190 Novel (3' UTR) 
6014 T> A 4 1/101 2/190 Novel 
(3，UTR)    
(• 
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Table 4-5. Summary of RHO & RPl disease-causing mutations detected in our 
study 
Subjects No. Mutations in RHO Mutations in RPl 
RP index patients 101 2 1 
Family members with RP ^ ^ ^ 
Family members without RP ig 0 0 
Usher syndrome 2 0 0 
Leber's congenital amaurosis 1 0 0 
Stargardt's disease 1 0 0 
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Figure 4-1. Differential migration of DNA heteroduplex and homoduplexes in CSGE. 
The heteroduplex is double-banded and the intensity of each band is about 
half that of the homoduplexes. 
(• 
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Figure 4-2. Comparison of sequencing results of wildtype and 5211delC in RHO 
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Figure 4-3. Comparison of sequencing results of wildtype and 521 IdelC in RHO 
using reverse primer. 
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Figure 4-4. Comparison of sequencing results of wildtype and Pro347Leu 
(CCG>CTG) in RHO. 
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Figure 4-5. Sequencing results of Ala299Ser (GCC>TCC) in RHO using forward or 
reverse primer. 
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Figure 4-6. Sequencing results of Arg677ter (CGA>TGA) in RPl using forward or 
reverse primer. 
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Figure 4-7. Comparison of sequence electropherograms of wildtype and Argl933ter 
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Figure 4-8. Family A with 521 IdelC in RHO. “+’’ mutation positive; “-“ mutation 
negative; DNA samples of the others were not available. 
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Figure 4-12. Family E with Arg677ter in RPL ‘‘+” mutation positive; ‘‘-“ mutation 
negative; DNA samples of the others were not available. 
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Figure 4-13. Family F with Argl933ter in RPL The index patient was with 
Stargardt's disease. “+” mutation positive; mutation negative. 
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Chapter 5 Discussion 
5.1 The Expected Frequencies of Patients with RHO & 
Mutations in Chinese RP Patients 
RHO mutations were reported to cause about 10% of all cases of RP and at 
least 25% of ADRP, and represent the most common known cause of the disease 
(http://www.sph.uth.tmc.edu/Retnet/). However, RHO mutations have been shown 
to contribute to a lower proportion of ADRP in Japan (Shiono et al., 1992; Saga et 
al., 1994). This is probably because the most frequent mutation, Pro23His, 
accounting for approximately one third of the rhodopsin-induced cases, is found 
only in North America and likely arose in a single ancestor (Dryja et al., 2000). 
Excluding Pro23His, the proportion of ADRP families with RHO mutations is 16-
18% (Bunge et al., 1993; Dryja et al., 2000), about 6-7% of all RP cases. Frequency 
of RHO mutations in Chinese RP patients has not been reported in the literature. In 
our study of Chinese RP patients, a novel polymorphism and a reported mutation in 
RHO were detected respectively, 5211 delC and Pro347Leu, both in exon 5. They 
are probable RHO mutations and are potentially useful for molecular diagnosis. The 
calculated frequency of RP patients carrying RHO mutations in this population is 
less than 7% (2/101 = 2.0%, 95% confidence interval: 0.2% - 7.0%) on the basis of 
these. Therefore the frequency is lower than that in North America, but more 
patients must be screened to confirm this trend. 
‘ RPl mutations have been reported to account for at least 7% of ADRP in North 
America (Pierce et a l , 1999; Sullivan et al., 1999; Bowne et a l , 1999). That was 
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about 3% of all RP cases in North America, more than any other identified gene 
besides RHO. In reports to date, disease causing RPl mutations have all been in 
exon 4，clustering between codons 658 and 1053, and lead to premature termination 
codons that are predicted to truncate the 2156-amino acid RPl molecule (Pierce et 
a l , 1999; Sullivan et al., 1999; Guillonneau et al., 1999; Bowne et al., 1999; 
Jacobson et a l , 2000). The Arg677ter (R677X) mutation, which has been reported 
by several research groups as present in approximately 3% of cases of ADRP in 
North America (Pierce et al., 1999; Sullivan et al” 1999; Bowne et al., 1999; 
Guillonneau et a l , 1999), is the third most common ADRP mutation in Caucasians 
after the RHO mutations Pro23His (12%) and Pro347Leu (5%) (Sharma et a l , 1999; 
Pierce et a l , 1999). However, no studies have yet reported RPl mutations in non-
Caucasians. In our study, Arg677ter was detected in one of 101 index patients. The 
calculated frequency of RP patients carrying RPl mutations in this population is less 
than 6% (1/101=1.0%, 95% confidence interval: 0.0%-5.4%). 
A summary of the numbers of mutations detected in RHO and RPl is given 
in Table 4-4. At least four possibilities may explain the lower frequency of 
mutations in these two genes in our study. First, the results in our study probably 
reflect the genetic differences between Chinese and Caucasian ethnic groups. 
Second, they may be due to the insufficient number of individuals that had been 
evaluated. Third, some RP patients may have extraocular abnormalities that have 
not been detected by ophthalmologists, such as Usher syndrome, Refsum disease or 
, Bardet-Biedl syndrome; others may have profound poor vision since birth, such as 
Leber's congenital amaurosis. Although these different diseases have clinical 
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appearances similar to RP, they are caused by genes other than RHO or RPl. 
Fourth, although CSGE was proven to be a reliable mutation detection method, its 
sensitivity varied from 86% to 100% (Ganguly et a l , 1993; Korkko et al.，1998; 
Markoff et al., 1998; Hinks et al” 1999). In our laboratory, it is close to 100% 
(Leung et al., 2001). Nevertheless, it is still possible that the protocols used in our 
study had missed some sequence changes. Genotyping more RP patients may 
uncover more novel mutations in these two genes and refine the frequency of their 
mutations in Chinese RP patients. 
5.2 The Mutation Screening Technique in this Study 
The mutation scanning techniques most commonly used for PGR products 
are single-strand conformation polymorphism (SSCP, Orita et al , 1989)，enzymatic 
or chemical cleavage of mismatched base pairs (Cotton et al.，1993; Youil et a l , 
1995)，and differential unfolding of homoduplexes and heteroduplexes by 
denaturing gradient gel electrophoresis (DGGE, Myers et al., 1987; Sheffield et al., 
1989). However, SSCP is not reliable with fragments of greater than about 300 bp, 
and the sensitivity is estimated to range from about 60% to 95% (Orita et a l , 1989; 
Cotton et al , 1993; Grompe et al., 1993; Eng et al” 1997; Nollau et a l , 1997). 
DGGE is highly sensitive, but it requires the use of GC clamps in one of the primers 
for each PGR product and a considerable effort to optimize conditions for analysis of 
a given gene (Myers et al., 1987; Sheffield et a l , 1989; Ritvaniemi et a l , 1993; 
Ritvaniemi et al., 1995). So far, CSGE has been suggested as a relatively simple, 
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sensitive and practical procedure for mutation scanning compared to the above 
methods (Ganguly et al., 1993; Korkko et al., 1998;Hinks et al.，1999; Lam et a l , 
2000). The only limitations that have been identified were that CSGE does not 
reliably detect mutations in the terminal 50 bp of each PGR fragment and that the 
optimal fragment size is between 200 and 450. To overcome such limitations, 
primers for PGR in this project were designed so that PGR products had at least 50 
base pairs of unimportant sequence at each end. The length range for CSGE was 
between 261 bp and 558 bp. For long exons, like exon 4 in RPl’ the PGR products 
were designed to overlap by about 100 base pairs. Using the above methods, a total 
of 24 sequence alterations including 23 single-base substitutions and one deletion 
were detected in our study. In our experience, CSGE does not give false positive 
results and can detect heteroduplexes with the PGR fragment size of 558 bp. 
Comparisons with data obtained by DNA sequencing showed that any PGR products 
that generate heteroduplexes by CSGE have at least one base mismatch, whereas 
none of the tested PCR products that produced homoduplexes was found to harbor a 
base mismatch. Thus, based on our results, it is believed that CSGE should not 
generate a significant number of false-positive or false-negative results. As 
commented by several authors (Korkko et a l , 1998; Markoff et a l , 1998; Hinks et 
al., 1999)，CSGE is sensitive to detect essentially all sequence variations when the 
primers are designed with the above requirements in mind. Besides its reliability, 
CSGE has the advantages over other methods for scanning PCR products in that it 
requires no special equipment or preparation of PCR products, since it uses a 
(• 
standard polyacrylamide electrophoretic gel in a modified solvent-buffer system. 
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The procedure is simple, requires little standardization, has a large capacity, and 
does not use radioactivity. Since RHO and RPl are ADRP-causing genes (i.e., 
mutations in either one of the alleles leads to the disease), mutations in these two 
genes should create heteroduplexes. Therefore, CSGE is a reliable method to detect 
mutations in these two genes. 
5.3 Mutations and Sequence Alterations Identified in RHO 
More than 100 mutations have been found in the rhodopsin gene. Most are 
missense mutations altering a single amino acid in the rhodopsin molecule. Up to 
now, fourteen naturally occurring mutations have been identified at the C terminal 
region of rhodopsin in RP patients (Tai et al., 1999). Both of the two mutations, 
Pro347Leu and 521 IdelC found in our study, also affected the rhodopsin carboxyl-
terminal tail. To our knowledge, 521 IdelC is a novel mutation and only the second 
single base pair deletion and the sixth small deletion known in RHO (The Human 
Gene Mutation Database: http://www.uwcm.ac.uk/uwcm/mg/search/120347.html). 
Although the two mutations may both be of class I rhodopsin mutants according to 
their relative positions, the phenotypes fell in different clinical categories of ADRP 
(Table 5-1). A nonpathogenic missense change, Ala299Ser, was detected in our 
study while the vast majority of the missense changes reported in RHO were disease 
causing. 
5.3.1 Novel mutation: 521 IdelC 
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The novel mutation, 521 IdelC, found in our study is a one base pair (C) 
deletion at codon 327 in exon 5 of RHO that causes a shift in the reading frame. It 
changes the last 22 codons and abolishes the normal stop codon at 349 in the 
carboxyl terminus, leading to a rhodopsin molecule with 10 extra amino acid 
residues (Figure 5-1). Most likely, 521 IdelC is an ADRP-causing mutation because 
the deletion segregated with RP in the family, whose pedigree showed an autosomal 
dominant inheritance (Figure 4-8), and even a single amino acid substitution in 
rhodopsin C-terminus (such as Pro347Leu) usually causes ADRP. This mutation is 
regarded as novel because it cannot be found in the literature or the RHO mutation 
databases online: 
• http://www.irpa.org/sci-news/rhomut.htm and 
• http://www.uwcm.ac.uk/uwcm/mg/search/120347.html. 
The mutation should result in rhodopsin protein with a radically altered 
carboxyl terminus that is 10 amino acids longer than normal. Regarding the 
mechanisms of this novel mutation, there are three possibilities. First, the charge of 
the carboxyl terminus is significantly altered by the loss of four negatively and the 
addition of nine positively charged residues (Figure 5-3). However, the effect of 
these structural alterations on the functioning of the protein is as yet unclear. 
Second, it is known that the phosphorylation of photoactivated rhodopsin, which 
modulates the potential to activate transducin, occurs largely at the carboxyl 
, terminal end. These phosphorylation sites are at the threonine and serine residues 
clustered in the last 15 amino acids of the protein (Sibley et a l , 1987). Recent in 
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vitro studies have disclosed that only the phosphorylation of serine/threonine 
residues at C-terminus of rhodopsin is effective in activating arrestin (McDowell et 
al , 2000). In the mutation 521 IdelC, all of the six threonine and serine residues are 
removed (Figure 5-3)，so that the mutant rhodopsin may not be able to undergo 
phosphorylation. Failure to activate arrestin may result in constitutively activated 
rhodopsin, resulting in continuously activated transducin. It is assumed that such a 
mutation causes cell death by over-stimulating the phototransduction pathway, 
analogous to exposure to constant light, which is known to cause photoreceptor cell 
death. But in another reported 1-bp deletion causing ADRP (Horn et a l , 1992), the 
deletion was at codon 340, closer to the end of C-terminus, the phosphorylation may 
not be affected since only three out of six threonine and serine residues were 
removed in that mutant rhodopsin. So finally, one might suggest the 1-bp deletion 
affects the highly conserved amino acid sequence of rhodopsin C-terminus which is 
involved in the transport of rhodopsin. 
The function of the C-terminal region in regulation of sorting and post-Golgi 
trafficking of rhodopsin has both in vitro and in vivo evidence (Sung et al , 1994; 
Deretic et a l , 1998; Chuang and Sung, 1998; Green et a l , 2000). The rhodopsin C-
terminal sequence QVAPA is highly conserved among different species (Deretic et 
al., 1998). Mutations in the rhodopsin C-terminus may lead to development of 
severe forms of ADRP (Berson et al” 1991; Sandberg et al” 1995; Macke et a l , 
1995). Deretic et al. in 1998 defined the C terminal of rhodopsin as the domain that 
regulates the trafficking of rhodopsin from the trans-Golgi network (TGN) to post-
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Golgi. They used an in vitro assay that reconstituted intra-Golgi trafficking as well 
as post-Golgi membrane formation from the TGN. Using this system, they chose 
synthetic peptides as competitive inhibitors of rhodopsin trafficking to explore 
further the role of the cytoplasmic domain of rhodopsin. Peptides corresponding to 
a 24-amino-acid sequence from the C terminus of rhodopsin inhibit post-Golgi 
trafficking of rhodopsin. However, these same peptides, when lacking QVS(A)PA, 
such as Gln344ter, or containing single amino acid substitutions, such as Val345Met 
and Pro347Ser, do not inhibit rhodopsin trafficking. In addition, this domain 
contains a novel cytoplasmic apical targeting determinant when expressed in 
polarized epithelial Madin-Darby canine kidney (MDCK) cells (Chuang and Sung, 
1998). In their study, removal of 32 amino acids from the cytoplasmic tail of 
rhodopsin results in a randomization of its membrane localization. Moreover, the 
addition of rhodopsin's cytoplasmic tail can redirect the sorting of other cytosolic 
proteins to the apical side of polarized MDCK cells. Independent observations by 
several groups studying mutations known to cause ADRP in transgenic animals 
support the above findings. Mice expressing the Gln344ter transgene (missing 
amino acids QVAPA) show nearly normal light response, but accumulate truncated 
rhodopsin in the plasma membrane of photoreceptor inner segments (Sung et al., 
1994). Abnormal accumulation of extracellular membranes containing rhodopsin 
has also been observed in mice carrying the proline 347 to serine (Pro347Ser) 
mutation (Li et al., 1996). 
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In addition to the functional consequences, 521 IdelC results in a 
degenerative process typical for RP (Table 5-1). The index patient with 521 IdelC 
had onset of nightblindness around age 30, and had visual acuity of 0.5/200 (right 
eye) and 5/200 (left eye) at age 53. Her daughter, who had no symptoms at age 26， 
was also found to harbor the mutation, and exhibited RPE mottling in both fundi. 
These data suggested that in spite of the largely altered carboxyl terminus, the onset 
of degeneration in the fourth decade in the patients with this mutation is later than 
the average onset age of ADRP in the second or third decades. Besides, we notice 
that at a similar age in their fifties, the patient with 521 IdelC had apparently worse 
visual acuity than the patient with Pro347Leu, indicating a concomitant loss of both 
rod and cone photoreceptor function. Therefore, patients with 521 IdelC at codon 
327 may fall into the type 2 of ADRP, the same category with another 1-bp del 
mutation at codon 340 (Gal et a l , 1997). 
5.3.2 Reported mutation: Pro347Leu 
This missense mutation was found in one index patient of ADRP. It is a C > 
T substitution at nucleotide 5271, changing codon 347 from proline (CCG) to 
leucine (CTG) in the C-terminus of rhodopsin. It is the most frequent of the six 
different ADRP mutations in the C-terminal domain involving substitutions of 
proline 347’ the others being Pro347Thr, Pro347Ala, Pro347Ser, Pro347Gln, and 
Pro347Arg (http://www.irpa.org/sci-news/rhomut.htni). Pro347Leu has been 
reported in different ethnic groups, and represents the most common RHO mutation 
in the world. It has been found in Europe (Ingleheam et al , 1992a), Asia (Fujiki et 
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al., 1992), and Africa (Greenberg et al., 1999) and has arisen independently more 
than once. 
However, its mechanism to cause RP is still unclear. The proline it affects 
may be critical for positioning the last amino acid, which is invariably alanine 
among different species, for binding within the hydrophobic pocket of the putative 
interacting protein involved in the rhodopsin sorting events (Deretic et al., 1998). 
Opsin-positive inclusions are prominent in rod inner segments of young transgenic 
pigs carrying a Pro347Leu porcine rhodopsin gene, suggesting that abnormal opsin 
may accumulate in the inner segment early in the process of rod cell degeneration 
(Li et al., 1998). The rods had short outer segments and delocalization of rhodopsin 
immunoreactivity to the surface membranes of their inner segments, somata, and 
synapses. Also, the absence of rhodopsin-immunoreactive Golgi organelles in the 
transgenic rods suggests that protein trafficking is defective in these cells, 
presumably a result of the presence of mutant rhodopsin. 
The mutation has been reported to cause severe rod degeneration with some 
cone preservation in humans (Berson et al., 1991b; Shiono et al., 1992; Fujiki et al., 
1992; Apfelstedt-Sylla et a l , 1992). With the several amino acid substitutions at 
position 347 of rhodopsin reported as causative for RP in humans, the disease 
expression in patients is consistently described as type 1 ADRP, with early onset of 
rod vision loss and slower diminution of cone-mediated visual function (Berson et 
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al., 1991b; Gal et al., 1997). The clinical findings in our patients with Pro347Leu 
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were therefore consonant with other examples of this mutation. When comparing 
the phenotypes of Pro347Leu and 521 IdelC mutations found in our study, we 
noticed that they fell in different clinical classes of ADRP (Table 5-1). Therefore, 
one may speculate that the presence of a proline residue at the carboxy terminus and 
its relative position, rather than its absolute position at codon 347，has an effect on 
determining clinical severity (Figure 5-3). Or perhaps the rhodopsin protein 
produced from the 521 IdelC mutation is degraded and cleared more rapidly than 
Pro347Leu rhodopsin. Another possible explanation is that phenotypes of RHO 
mutations are modified by some unknown environmental factors or other genes. 
Future in vitro or in vivo studies on the mutant rhodopsin may help to elucidate these 
problems. 
5.3.3 Novel nonpathogenic missense change: Ala299Ser 
Neutral amino acid substitutions in rhodopsin are extremely rare. Sung et al. 
(1991a) screened 322 rhodopsin genes, found 39 carrying mutations responsible for 
ADRP and none carrying an amino acid substitution unrelated to ADRP. So far, 
there are only two nonpathogenic missense changes reported. Recently, Dryja et al. 
(2000) reported Phe220Leu as only the second known nonpathogenic missense 
change in the human rhodopsin gene, Vall04Ile being the first (Macke et al., 1993). 
In our study, Ala299Ser was found in both an index patient and two of the controls. 
The alanine at codon 299 is not well conserved among mammals (Table 5-2). 
Among 65 vertebrate opsins, only 27 have Ala at this position, all the others have 
serine instead (www.gpcr.org/7tm). Serine can be thought of as a hydroxylated 
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version of alanine. The hydroxy! groups on serine make them much more 
hydrophilic and reactive than alanine. These may help to explain why this missense 
change is well tolerated in humans. However, sequence alterations that would 
change the alanine at codon 299 into amino acids other than serine may still cause 
RP. 
5.3.4 Novel silent sequence alterations 
There were three silent sequence alterations detected in RHO, Thr62Thr in 
exon 1, Leu259Leu in exon 4 and Thr340Thr in exon 5. Each was found in one of 
the index patients respectively. Although they have not been found in any of the 
190 controls, they are most likely not related to RP because the amino acids they are 
coding are not changed. Other silent sequence alterations found in RHO were 
ProlOVPro (Gal et al., 1997), Glyl20Gly (Dryja et al., 1991), Thrl60Thr (Sung et 
al., 1991a), Alal73Ala (Dryja et al., 1991)，Lys248Lys (Sung et al , 1991a), and 
Ser297Ser (Saga et al., 1994). They were all reported as most likely non-pathogenic 
rare sequence variants. 
5.3.5 Other polymorphisms in RHO 
Three polymorphisms were detected in the non-coding region of RHO in our 
study. They are 269A>G in the 5' UTR, 5145G>A in intron 4 and 5321C>A in the 
3’ UTR. The frequencies of 269A>G, 5145G>A, and 5321C>A were 1%, 30%, and 
(• 
12%, respectively. There were no significant differences in the frequencies of RP 
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patients and controls. All of these three have been reported to be polymorphisms 
and most likely non-pathogenic sequence variants in North America (Dryja et al., 
1990c; Dryja et al., 1991; Sung et al.，1991a) and Japan (Kawano et al.，1995). 
5.4 Mutation and Sequence Alterations Detected in RPl 
In reports to date, disease-causing RPl mutations have all been in exon 4， 
clustering between codons 658 to 1053, and lead to premature termination codons 
that are predicted to truncate the RPl molecule (Jacobson et al” 2000). Naturally 
occurring variants have been extremely useful in studies of protein structure and 
function. However, the function of RPl is unclear and no studies have yet reported 
RPl mutations in non-Caucasians. 
A recent study on RPl and Rpl proteins indicated the complete RPl/Rpl 
open reading frames (ORFs) might not be translated, but rather those internal 
initiation codons were used (Liu et al., 2000). In their study, the human and mouse 
RPl/Rpl proteins had apparent molecular weights of approximately 175-180 kDa, 
as determined by SDS-PAGE. These were lower than the predicted 235-240 kDa 
for translation of the entire ORFs. They pointed out that the first ATG did not 
match Kozak rules in the human protein. Possible examples of initiation codons that 
match Kozak consensus sequences are human codon 394 and mouse codon 428, 
which would produce proteins of 196 and 186 kDa if used. This implies that the 
nonsense mutations detected to date would truncate the protein at a more N-terminal 
(• 
location than previously hypothesized. 
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5.4.1 Mutation found in Chinese: Arg677ter 
This nonsense mutation at codon 677 of RPl, leading to a severely truncated 
protein, was detected in one of the 101 index patients. It was reported to be present 
in approximately 3% of cases of dominant RP in North America, i.e., 1% of all RP 
cases. It is considered as the third most frequently identified mutation causing 
dominant RP after the Pro23His (9% of cases) and Pro347Leu (4% of cases) 
mutations in RHO. 
-associated disease has been briefly described in many molecular reports 
during the past two decades. In linkage studies of the extensive ADRP UCLA-RPOl 
pedigree, now known to be caused by an Arg677ter RPl mutation (Pierce et al.， 
1999; Sullivan et al , 1999), it was mentioned that the disease shows 1) night 
blindness in the second and third decades of life and "blindness by ages 45 to 60” 
(Spence et al., 1977; Heckenlively et al , 1982); 2) "diffuse retinal pigmentation, 
progressive decrease in recordable ERGs, concentric visual field loss," and two 
possible instances of incomplete penetrance (Daiger et al., 1989); and 3) "classic 
type 2 ADRP," defined as “regionalized and combined loss of rod and cone 
sensitivities on psychophysical testing’，(Blanto et al , 1991). In our study, the index 
patient harboring Arg677ter was also from an ADRP pedigree (Figure 4-12) and 
became symptomatic at as late as 30 years old. Her fundus appearance was 
described as moth-eaten RP. The progression of the disease seems to be fast since 
, the best VA at 47 years old was only 20/200 (Table 5-1) and there were extinguished 
‘a，and 'b' waves in both scotopic and photopic ERG, probably due to concomitant 
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loss of both rod and cone photoreceptor function. These findings were compatible 
with those of type 2 ADRP. One interesting phenomenon is that the patient also had 
Fuchs' corneal endothelial dystrophy, which is another autosomal dominant 
hereditary disease, in her right eye. This association has not been mentioned before 
in the literature. 
Nevertheless, substantial variability of disease severity, which seems to be a 
feature of the RPl form of ADRP, suggested that other genetic and nongenetic risk 
factors might be involved in RPl disease expression. Our study indicates that 
phenotypic similarities exist among patients with the Arg677ter mutation of 
different racial backgrounds. As the function of RPl is as yet unclear, we can only 
assume that the severely truncated protein caused by the mutation may lose some 
important functional domains. 
5.4.2 Novel nonsense sequence alteration: Argl933ter 
Argl933ter was found heterozygously in one control subject, a patient with 
Stargardt's disease and his two normal family members. To date, the reported 
ADRP-causing RPl mutations have all been in exon 4，clustering in the region 
between codons 658 and 1053, such as Arg677ter, Leu762-763 (5-bp del), and the 
Tyr 1053 (1-bp del) causing the most C-terminal truncation known at present 
(Jacobson et al., 2000). However, the RPl protein is more severely truncated by 
these reported mutations than the RPl mutant Argl933ter found in our study. The 
(• 
finding of several normal subjects carrying Argl933ter in our study implies that it is 
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probably the first non-pathogenic nonsense change identified in the coding region of 
RPL This benign variant also implies that codon 1053-1933 may contain some 
important functional domains, such as a possible transmembrane domain (codon 
1120-1142) or a leucine-zipper motif (codon 1396-1417) suggested by Pierce et al. 
(1999). It also implies that the carboxyl terminal 224 amino acids of the RPl 
molecule may not be essential for its function. 
5.4.3 Novel missense and non-coding changes in RPl 
Met4791le 
Met479Ile was found in exon 4 of RPl, in a 66-year-old RP index patient but 
not in any of the 190 controls. The only available family member of the index 
patient was her 30-year-old son, who had no symptoms or signs of RP but also 
carried Met479Ile. Regarding the proband's late onset of disease at 60，and the good 
visual acuity at 66 years old with mild fundal change, the possibility that the son 
may develop RP in his late life cannot be ruled out at present. Based on the 
preliminary results, one cannot exclude the possibility that the above sequence 
alteration may be disease causing. 
Other novel sequence alterations 
There were seven other novel missense sequence alterations found in exon 4 
of RPl in our study that were most likely benign variants in RPL They were 
, Arg249His, Gly706Arg, GlnlOOSGln, Glnl063Arg, Ile214lMet, 5880 C>T (3’ 
UTR) and 6014 T � A (3，UTR). All could be found in the normal controls, except 
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for Arg249His. However, Arg249His did not segregate with the disease in the 
family. Gly706Arg was also found in normal family members of the index patient. 
To be precise, Glnl063Arg and Ile2141Met were only found in controls but not in 
patients. These results support the hypothesis that all of the disease-causing 
mutations found so far involve large disruptions of the RPl protein and that amino 
acid substitutions are not usually detrimental. Further support to this hypothesis is 
the finding of an unusual degree of sequence divergence among mammalian RPl 
genes. Sullivan et al. (2000) pointed out that, at the amino acid level, the mouse and 
human RPl proteins are only 60% identical while the human and mouse rhodopsin 
proteins are 94% identical. So the whole sequence of RPl may not be as critical as 
that of RHO. 
5.4.4 Reported polymorphisms 
There were five reported polymorphisms found in our study. They were 
Arg872His, Asn985Tyr, Alal670Thr, Ser 1691 Pro and Cys2033Tyr. Interestingly, 
Asn985Tyr and Cys2033Tyr were always found together in an individual, and 
Alal670Thr always co-existed with Ser 1691 Pro. Sullivan et al. (1999) reported the 
above five polymorphic amino acid substitutions in unaffected controls without 
mentioning the links between Asn985Tyr and Cys2033Tyr, or Alal670Thr and 
Ser 1691 Pro. Recently, Jacobson et al. (2000) noticed that the codon 1670 and 1691 
polymorphisms were found together in all 115 cases. Therefore, Alal670Thr and 
‘ Ser 1691 Pro seem to be linked in both Caucasian and Chinese ethnic groups. 
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5.5 Possible Functions of RPl 
On the basis of the time course and location of its expression, RPl is 
possibly involved in the differentiation of photoreceptor cells. The protein is 
photoreceptor-specific and has a 187 amino acid region of homology with 
doublecortin (DCX), which was hypothesized to be involved in directing neuronal 
migration during the development of the central nervous system (Gleeson et al., 
1999). The similarity to DCX suggests it may have a role in development or 
maintenance of the neural retina or neuronal components of photoreceptor cells 
(Pierce et al., 1999). The predicted amino acid sequence also has a 149 amino acid 
region homologous with the Drosophila melanogaster protein BIF (encoded by the 
gene bifocal, bif), which is required for normal photoreceptor morphogenesis (Bahri 
et al , 1997). This homology suggested a role for RPl in photoreceptor structure or 
metabolism (Pierce et al., 1999). The presence of a leucine zipper motif indicates it 
may function as a transcriptional regulator in photoreceptors (Landschulz et a l , 
1988). 
In our study, the finding of several normal subjects heterozygous for an RPl 
truncating mutation at codon 1933 implies that a normal level of the C-terminal 224 
amino acids of RPl is not necessary for preventing development of RP. However, 
truncation due to a 1-bp deletion at codon 1053 causes RP (Jacobson et al.，2000). 
Therefore at least part of the RPl protein between amino acids 1052 and 1933 must 
be present at undiminished levels in order to maintain healthy photoreceptor 
function. This region contains a possible transmembrane domain (1120-1142) and 
9 9 
leucine-zipper motif (1396-1417) (Pierce et al., 1999). Thus deletion of these sites 
may prevent proper subcellular localization to a membrane or disrupt a possible 
protein or DNA-binding function of RPl. Screening more study subjects, including 
patients and controls, may identify truncations within this critical region and help to 
narrow its width, thereby shedding light on the possible role of RPl in both normal 
eye function and in RP. 
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Table 5-2. Alignment of amino acid sequences encoded by codon 296 to 302 in 
RHO among different mammals 
Mammals Codon 296-302 in opsin 
Rabbit K S S S I Y N 
Mouse K S S S I Y N 
Sheep K S S S V Y N 
Pig K S A S I Y N 
Bovine K T S A V Y N 
Human K S A A I Y N 
(• 
1 0 2 
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codons 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 
wild type cca ctg ggt gac gat gag gcc tct get acc gtg tcc aag acg gag acg age cag gtg gcc ccg gcc taa 
P L G D D E A S A T V S K T E T S Q V A P A 
_ _ _ * * * * _ * 氺 
P347L cca ctg ggt gac gat gag gcc tct get acc gtg tcc aag acg gag acg age cag gtg gcc ctg gcc taa 
P L G D D E A S A T V S K T E T S Q V A L A 
Ibp cac tgg gtg acg atg agg cct ctg eta ccg tgt cca aga egg aga cga gcc agg tgg ccc egg cct aag 
deletion H W V T M R P L L P C P R R R R A R W P R P K + + + + + + + + + 
acc tgc eta gga ctc tgt ggc cga eta tag 
T C L G L C G R L 
+ 
Figure 5-2. Partial nucleotide and amino acid sequences of wildtype and mutant 
rhodopsin C-terminus implicated in our study. * Potential 
phosphorylation sites; + Positively charged residue; - Negatively 
charged residue. 
(• 
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Chapter 6 Conclusions 
1. The expected frequency of RP patients carrying RHO mutations among all Hong 
Kong Chinese RP patients is less than 7% (2/101 = 2.0%, 95% confidence 
interval: 0.2% - 7.0%). 
2. The 1-bp deletion, 521 IdelC, is a novel mutation and probably disease-
causative. It is the second 1 -bp deletion detected in RHO. 
3. The novel missense polymorphism, Ala299Ser, appears to be only the third non-
pathogenic missense change found in RHO. 
4. This is the first study to report a probable mutation in RPl in ethnic Chinese RP 
patients. The expected frequency of RP patients carrying RPl mutations among 
all Hong Kong Chinese RP patients is less than 6% (1/101=1.0%, 95% 
confidence interval: 0.0%-5.4%). 
5. The Argl933ter, a novel nonsense polymorphism, is the first benign variant 
causing truncation of the RPl protein. 
6. A normal level of at least part of RPl between amino acids 1052 and 1933 
appears necessary to prevent RP. However, a normal level of the C-terminal 224 
amino acids of RPl is not necessary for preventing development of RP, 
7. The unexpectedly large number of probable benign variants may indicate that 
amino acid substitutions in RPl are not usually detrimental. 
8. Molecular diagnosis for RP using RHO and RPl mutations appears to be feasible 
in the local population. 
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